Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  12-Aug-2021A Phase 2a Single-Arm, Open-Label, Multicenter Exploratory Study 
to Assess the Effects of Sotatercept (ACE-011) for the Treatment of 
Pulmonary Arterial Hypertension
&OLQLFDO6WXG\3URWRFRO 6 RWDWHUFHSW$&(
6WXG\1R$5HYLVLRQ
$XJXVW
$FFHOHURQ3KDUPD,QF 3DJHRI &21),'(17,$/3URWRFRO$
3URWRFRO7LWOH
$3KDVHD6LQJOH$UP2SHQ/D EHO0XOWLFHQWHU([SORUDWRU\6WXG \WR$VVHVVWKH(IIHFWVRI
6RWDWHUFHSW$&(IRUWKH 7UHDWPHQWRI3XOP RQDU\$UWHULDO+ \SHUWHQVLRQ
6KRUW7LWOH
$3KDVHD2SHQ/DEHO([SORUDWRU\6WXG\RI6RWDWHUFHSWIRUWKH 7UHDWPHQWRI3$+
6321625  $FFHOHURQ3KDUPD,QF 
6LGQH\6WUHHW 
&DPEULGJH0$86$ 
7HO 
5HJXODWRU\$JHQF\
,GHQWLI\LQJ1XPEHUV ,1'
25,*,1$/[ZIP_CODE]&2/'$7( -XO\
[ZIP_CODE]&2/$0(1'0(17 6HSWHPEHU
[ZIP_CODE]&2/$0(1'0(17  'HFHPEHU
[ZIP_CODE]&2/$0(1'0(17$ 2FWREHU
[ZIP_CODE]&2/$0(1'0(17 -XQH
[ZIP_CODE]&2/$0(1'0(17 $XJXVW
&RQILGHQWLDOLW\6WDWHPHQW
7KLVFRQILGHQWLDOLQIRUPDWLRQLQ WKLVGRFXPHQWLVSURYLGHGWR\ RXDVDQLQYHVWLJDWRURUFRQVXOWDQWIRUUHYLHZE\\RX
\RXUVWDIIDQGWKHDSSOLFDEOH,Q VWLWXWLRQDO5HYLHZ%RDUG,5% ,QGHSHQGHQW(WKLFV&RPPLWWHH,(&<RXU
DFFHSWDQFHRIWKLVGRFXPHQWFRQVWLWXWHVDJUHHPHQWWKDW\RXZLOO QRWGLVFORVHWKHLQIRUPDWLRQFRQWDLQHGKHUHLQWR
RWKHUVZLWKRXWZULWWHQDXWKRUL]DWLRQIURP$FFHOHURQ3KDUPD,QF [COMPANY_003]
:%/
Clinical Study Protocol  Sotatercept (ACE-011) 
Study No: A011-10Revision: [ADDRESS_184660] 2021 
Acceleron Pharma Inc. Page 2 of 93 CONFIDENTIAL  
Signature [CONTACT_159136]:  
Date:  
 
Name (print):    
   
Investigator Agreement:  I have read the protocol and agree to conduct the study as outlined 
in the protocol.  The study will be conducted in accordance with current [LOCATION_002] Food 
and Drug Administration (FDA) regulations, International Council for Harmonisation (ICH) 
Guidelines, Good Clinical Practices (GCP), the Declaration of Helsinki, and local ethical and legal requirements. 
 
Signature:  [CONTACT_1782]:  
 
Name (print):  
  
  
    
Institution Name [CONTACT_1781]:   
    
    
    
 
 [COMPANY_003]
:%/
&OLQLFDO6WXG\3URWRFRO 6 RWDWHUFHSW$&(
6WXG\1R$5HYLVLRQ
$XJXVW
$FFHOHURQ3KDUPD,QF 3DJHRI &21),'(17,$/352&('85(6,1&$6(2)(0(5*(1&<
7DEOH (PHUJHQF\&RQWDFW,QIRUPDWLRQ
5ROHLQ6WXG\ 1DPH &RQWDFW,QIRUPDWLRQ
0HGLFDO0RQLWRU $FFHOHURQ3KDUPD,QF
6LGQH\6WUHHW 
&DPEULGJH0$86$ 



3KDUPDFRYLJLODQFH 9DULRXV 33'6DIHW\+RWOLQH
3DUDPRXQW3DUNZD\ 
0RUULVYLOOH1& 86$
3KRQH[COMPANY_003]
[COMPANY_003]
:%/
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184661]  2021 
Acceleron Pharma Inc.  Page 4 of 93 CONFIDENTIAL  Protocol Amendment Summ
ary of Changes Table  
Substantive changes from the
 Protocol Amendment 0 4 (18 June 2020 ) to Protocol Amendment 
05 ([ADDRESS_184662]  2021) are detailed below.  Minor edits are not i
ncluded.  See  Appendix  [ADDRESS_184663] of the Protocol Amendment History.  
Protocol Location  Description of Change  Brief Rationale  
Cover Page  Added: PROTOCOL 
AMENDMENT [ADDRESS_184664] (iCPET).   To clarify that part
icipants are 
eligible, upon complet
ion of the 
third iCPET, to trans
ition to the 
sotatercept long -term follow -up 
study.  
Secti on 2, Schedule of 
Events  Added footnote to the Sche
dule of 
Events for the Extension P
eriod 
(Table 4 ). To clarify that part
icipants who 
complete the third 
iCPET and 
consent to the sotate
rcept long -term 
follow -up study will be asked to 
complete the End of Tr eatment Visit 
only.  
Section 4.7, Follow -Up 
Period  Combined subsections 4.7.1. (End of
 
Treatment or Discont
inuation of 
Study Drug; End of Study) and 
4.7.2. (Extension Period)  To simplify definiti
on of Follow -Up 
Period.  
Section 4.9, End of  Study 
Definition  End of Study (EOS) visits a
re only 
required for parti
cipants who 
discontinue the study earl
y or 
decline transition t
o the sotatercept 
long-term follow -up study.  To clarify EOS requirem
ent for early 
discontinuation or decli
ning 
transition to the sotatercep t long -
term follow -up study.  
Section 8.2.1, Efficacy  
Assessments, iC
PET Updated iCPET being perfor
med at 
Cycle [ADDRESS_184665] Cycl
e timepoint  
EOS = End of Stud
y; iCPET  = Invasive Cardiopu
lmonary Exercise Test  
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184666] ION ................................ ................................ ................................ ......18 
3.1. Study Rationale  ................................ ................................ ................................ ........... 18 
3.2. Rationale for Patient Population  ................................ ................................ ................. 19 
3.3. Rationale for Study Endpoints  ................................ ................................ .................... 19 
3.4. Rationale for Dose Level
 and Frequency Selection  ................................ ................... 21 
3.4.1.  Treatment Period  ................................ ................................ ................................ ........ 21 
3.4.2.  Extension Period  ................................ ................................ ................................ ......... 21 
3.5. Backg round  ................................ ................................ ................................ ................. 21 
3.6. Benefit/Risk Assessment  ................................ ................................ ............................ [ADDRESS_184667] of Care  ................................ ................................ ................................ ......... 25 
4.4. Screening Period  ................................ ................................ ................................ ......... 25 
4.5. Treatment Period  ................................ ................................ ................................ ........ 25 
4.6. Extension Period  ................................ ................................ ................................ ......... 25 
4.7. Follow -Up Period  ................................ ................................ ................................ .......26 
4.8. Partici pant and Study Completion  ................................ ................................ .............. 28 
4.8.1.  Extension Period  ................................ ................................ ................................ ......... 28 
4.9. End of Study Definition  ................................ ................................ .............................. 28 
4.10.  Justification for Dose  ................................ ................................ ................................ ..28 
5. STUDY POPULATION  ................................ ................................ ............................. 29 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 29 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......30 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: 05 
Page 6 of 93 CONFIDENTIAL  5.3. Scree n Failures  ................................ ................................ ................................ ............ 32 
6. TREATMENTS  ................................ ................................ ................................ .......... 33 
6.1. Treatments Administered  ................................ ................................ ............................ 33 
6.2. Treatment Administration and S
chedule  ................................ ................................ ....33 
6.3. Dose Modification  ................................ ................................ ................................ ......33 
6.4. Method of Treatment Assignment  ................................ ................................ .............. 37 
6.5. Randomization and Blinding  ................................ ................................ ...................... 37 
6.6. Packaging and Labeling  ................................ ................................ .............................. 37 
6.7. Preparation/Handling/Storage/Ac
countability  ................................ ............................ 37 
6.8. Treatment Compliance  ................................ ................................ ................................ 38 
6.9. Concomitant Therapy  ................................ ................................ ................................ .38 
7. DISCONTINUATION/
WITHDRAWAL CRITERIA  ................................ ............... [ADDRESS_184668] to Follow -Up................................ ................................ ................................ .......40 
8. STUDY ASSESSMENTS AND PROCEDU
RES ................................ ...................... 41 
8.1. Screening Procedures  ................................ ................................ ................................ ..41 
8.2. Efficacy Assessments  ................................ ................................ ................................ .41 
8.2.1.  iCPET  ................................ ................................ ................................ ......................... 41 
8.2.2.  Cardiac Magnetic Re
sonance Imaging  ................................ ................................ .......42 
8.2.3.  Pulmonary Vascular Resistanc
e by [CONTACT_159085]  ............................... 43 
8.2.4.  Six-Minute Walk Distance  ................................ ................................ ......................... 43 
8.3. Adverse Events  ................................ ................................ ................................ ........... 44 
8.3.1.  Adverse Event Definitions  ................................ ................................ .......................... 44 
[IP_ADDRESS].  Adverse Events  ................................ ................................ ................................ ........... 44 
[IP_ADDRESS].  Unexpected Adverse Events  ................................ ................................ ....................... 44 
[IP_ADDRESS].  Events Not to Be Considered as Adve
rse Events  ................................ ....................... 44 
[IP_ADDRESS].  Serious Adverse Event  ................................ ................................ ................................ 44 
[IP_ADDRESS].  Events Not to Be Considered as Se
rious Adverse Events are Hospi[INVESTIGATOR_22037]: ................................ ................................ ................................ ............................... 45 
[IP_ADDRESS].  Severity  ................................ ................................ ................................ ....................... 46 
8.3.2.  Relationship to Study Drug  ................................ ................................ ........................ 46 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184669]  ................................ ................................ ............. 51 
8.5. Safety Assessments  ................................ ................................ ................................ .....52 
8.5.1.  Physical Examinations  ................................ ................................ ................................ 52 
8.5.2.  Vital Signs  ................................ ................................ ................................ .................. 52 
8.5.3.  Electrocardiograms  ................................ ................................ ................................ .....53 
8.5.4.  Clinical Worsening  ................................ ................................ ................................ .....53 
8.5.5.  Rescue Therapy Criteria  ................................ ................................ ............................. 53 
8.5.6.  Clinical Safety Laboratory Assessm
ents ................................ ................................ ....54 
8.6. Pharmacokinetics  ................................ ................................ ................................ ........ 54 
8.7. Pharmacodynamics  ................................ ................................ ................................ .....55 
8.8. Genetic Testing  ................................ ................................ ................................ ........... 55 
9. STATISTICAL CONSID
ERATIONS  ................................ ................................ .......56 
9.1. Sample Size Determinati
on ................................ ................................ ........................ 56 
9.2. Populations for Analyses  ................................ ................................ ............................ 56 
9.3. Statistical Analyses  ................................ ................................ ................................ .....56 
9.3.1.  Efficacy Analyses  ................................ ................................ ................................ .......57 
9.3.2.  Safety Analyses  ................................ ................................ ................................ .......... 57 
9.3.3.  Other Analyses  ................................ ................................ ................................ ............ 58 
9.3.4.  Primary Endpoint Analysis  ................................ ................................ ......................... 58 
9.3.5.  Extension Period Analysis  ................................ ................................ .......................... 58 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184670] ................................ ..................... 71 
APPENDIX  6. CARDIAC MAGNETIC RESONAN
CE IMAGING  ................................ ........ 72 
APPENDIX  7. STUDY GOVERNANCE CONSI
DERATIONS ................................ ............... 73 
APPENDIX  8. CONTRACEPTIVE GUIDANC
E AND COLLECTION OF 
PREGNANCY INFORMATION  ................................ ................................ ............... 77 
APPENDIX  9. GENETICS  ................................ ................................ ................................ ......... 80 
APPENDIX  10. PROTOCOL AMENDMENT HISTOR
Y ................................ ........................ 81 
 
  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184671] OF TABLES  
Table  1: Emergency Contact [CONTACT_7171]  ................................ ................................ ................... 3 
Table  2: Objectives and Endpoints  ................................ ................................ ........................... 11 
Table  3: Schedule of Events  ................................ ................................ ................................ .....13 
Table  4: Schedule of Events: Extension and Foll
ow-Up Periods  ................................ ............. 16 
Table  5: Objectives and Endpoints  ................................ ................................ ........................... 23 
Table  6: Dose Reductions for Sotaterc
ept ................................ ................................ ................ 37 
Table  7: Identified Risks  ................................ ................................ ................................ ........... 50 
Table  8: Potential Risks  ................................ ................................ ................................ ............ 51 
Table  9: Adverse Events of Special Int
erest  ................................ ................................ ............. 51 
Table  10: Statistical Analysis of Endpoints  ................................ ................................ ................ 57 
Table  11: Protocol -Required Safety Laboratory Ass
essments  ................................ ................... 66 
Table  12: Highly Effective Contraceptive
 Methods  ................................ ................................ ...78 
Table  13: Protocol Amendment 03A to Protocol Amendment 04 Amendment History  ............ 81 
Table  14: Protocol Amendment 02 to Protocol Amendment 03A Amendment History  ............ 86 
Table  15: Protocol Amendment 01 to Protocol Amendment 02 Amendment History  ............... 91 
Table  16: The Original Protocol to Protocol Amendment [ADDRESS_184672] OF FIGURES  
Figure  1: Study Design  ................................ ................................ ................................ ............... 27 
Figure  2: Platelet Count Dose Modification: Dose Delay, 
Dose Reduction and 
Discontinuation Guidelines  ................................ ................................ ........................ 35 
Figure  3: Hemoglobin Dose Modification: Dose Delay, Dos
e Reduction and 
Discontinuation Guidelines  ................................ ................................ ........................ 36 
 
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184673]  2021 
Acceleron Pharma Inc.  Page 10 of 93 CONFIDENTIAL  1. SYNOPSIS  
Protocol Title  
A Phase 2a Single -Arm, Open -Label, Multicenter Exploratory Study t
o Assess the Effects of 
Sotatercept (ACE -011) for the Treatment of Pulmonary A
rterial Hypertension  
Short Title  
A Phase 2a Open -Label Exploratory Study of Sotatercept for the Tre
atment of PAH  
Clinical Sites   
Approximately five clinical sites in the
 [LOCATION_002].  
Rationale  
Study A011 -10 is a Phase 2a, single -arm, open -label, multicenter exploratory study to determine 
the effects of sotatercept (AC
E-011) in adults with World Health Organizati
on (WHO) Group 1 
functional class III pulmonary hypertension
 or pulmonary arterial hy pertension (PAH).  These 
patients experience marked li
mitations in physical activity and are at significant risk for disease 
progression and death.[ADDRESS_184674] tha
t treatment with sotatercept 
may reduce muscularization and thickness of pulmonary ve
ssel walls, right -sided heart pressures, 
and right -to-left ventricle weight ratios.2  These improvements may be acco
mpanied by 
[CONTACT_159086], and right 
ventricular mechanics and functi
on, all of which will be measured during the study.  
  
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184675]  2021 
Acceleron Pharma Inc.  Page 11 of 93 CONFIDENTIAL  The main objectives and endpoints for this study are found in Table  2. 
Table  2: Objectives and Endpoints 
Objectives  Endpoints  
Primary  
To evaluate the effect of sotatercept  on an 
invasive cardiopulmonary exercise test 
(iCPET) measure in PAH patients treated with 
sotatercept plus standard of care (SOC)  Change from baseline in VO 2 max at 24  weeks  
Secondary 
â€¢To evaluate the effect of sotatercept  on
additional measures in PAH patients
treated with sotatercept plus SOC
â€¢To evaluate effects of sotatercept on
right ventricular stroke volume
(RV SV), RV  end-systolic volume
(RV ESV), RV  end-diastolic volume
(RV EDV), RV  ejection fraction
(RV EF), RV str oke volume index
(RV SVI), and RV mass in PAH
patients treated with sotatercept plus
SOCâ€¢Exercise measures, including change in
VE/VCO 2 slope (ventilatory efficiency),
cardiac index, mean pulmonary arterial
pressure, and Ca -vO 2 (arteriovenous O 2 
content di fference) at 24 weeks
â€¢Change from baseline in RV  SV, RV  ESV,
RV EDV, RV  EF, RV  SVI, and RV mass
by [CONTACT_159087] (MR)
imaging at 24  weeks
iCPET = invasive cardiopulmonary exercise test; PAH = pulmonary arterial hypertension; PVR = pulmonary 
vascular resistance; RV EDV = right ventricular end -diastolic volume; RV EF = right ventricular ejection fraction; 
RV ESV = right ventricular end -systolic volume; RV SV = right ventricular stroke volume; RV SVI = right 
ventricular stroke volume index; SOC =  standard of care; VO 2=peak oxygen uptake.  
Overall Design  
This is a Phase 2a, single -arm, open -label, multicenter, exploratory study assessing the efficacy 
and safety of sotatercept for the treatment of WHO Group [ADDRESS_184676] of care (SOC) plus sotatercept  at a dose of 
0.3 mg/kg SC for Cycle 1 and escalating to 0.7 mg/kg at Cycle [ADDRESS_184677] of care ( SOC ) therapy refers to combination therapy consisting of drugs from two or 
more of the following drug classes: an endothelin -receptor antagonist (ERA), a 
phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or  a 
prostacyclin analogue or receptor agonist.  Patients receiving monotherapy are not to be enrolled. 
During the Extension Period, participants under investigatorâ€™s supervision can substitute, 
remove, or adjust the dose of SOC for PAH -worsening and chroni c concomitant medications, 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184678] (iCPET) . 
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184679] 2021 
Acceleron Pharma Inc.  Page 13 of 93 CONFIDENTIAL  2. SCHEDULE OF EVENTS  
Table  3: Schedule of Events  
 Screening 
Period  
(up to 28 
days 
before 
Cycle 1 
Day 1)  Treatment Per
iod (24 Weeks)1 
Cycle 1  Cycle 2  Cycle 3  Cycle 4  Cycle 5  Cycles  
6-7 Cycle 8  Cycle 9  
Day 1  Day 8  Day 22  Day 29  Day 43  Day 64  Day 85  Day 106;  
Day 127  Day 148 Day 169  
Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  
Informed consen
t X           
Inclusion/ e
xclusion 
criteria  X           
Medical hist
ory X           
Physical exa
mination2 X X  X  X X X X X X 
Vital signs  X X X X X X X X X X X 
Pregnancy te
st3 X X  X  X X X X X X 
Hematology4 X X X X X X X X X X X 
Serum chemistr
y X X  X  X X X X X X 
Urinalysis   X      X   X 
12-lead ECG  X X  X        
Pulmonary te
sts5 X           
Anti-drug antibod
y 
(ADA)   X  X  X X X X X X 
Genetic sample   X          
Cardiac MR6 X          X 
6MWT7 X       X   X 
RHC + CPET (iC
PET)8 X          X 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184680] 2021 
Acceleron Pharma Inc.  Page 14 of 93 CONFIDENTIAL   Screening 
Period  
(up to 28 
days 
before 
Cycle 1 
Day 1)  Treatment Pe
riod (24 Weeks)1 
Cycle 1  Cycle 2  Cycle 3  Cycle 4  Cycle 5  Cycles  
6-7 Cycle 8  Cycle 9  
Day 1  Day 8  Day 22  Day 29  Day 43  Day 64  Day 85  Day 106;  
Day 127  Day 148 Day 169  
Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  Â±3 
days  
Transpulmona
ry flux 
biomarkers9 X          X 
WHO Functio
nal Class 
Assessment  X X  X  X X X X X X 
Clinical wo
rsening   X  X  X X X X X X 
PK collecti
on  X  X  X  X  X X 
PD blood bi
omarkers   X  X    X  X X 
Study drug 
administrati
on10  X  X  X X X X X X 
AE/SAE review11 X11 X X X X X X X X X X 
Concomitant
 medication 
review  X X X X X X X X X X X 
Abbreviations: 6MWT = [ADDRESS_184681]; ADA = an
ti-drug antibody; A
E = adverse event; CTPA = computed tomography pu
lmonary angiogram; 
ECG  = electrocardiogram; 
eCRF = electronic case report form; Hgb = hemoglobin; iCPET = invasive cardiopulmonary exercise test; MR =  magnetic resonance; 
PD = pharmacodyn
amic(s); PK = pharmacokinetic(s); RHC = right heart cath eterization; SAE = serious
 adverse event; VQ = ventilation -perfusion; 
WHO  = World Health Organ
ization.  
[ADDRESS_184682] udy drug.  Cycles are every 3 
weeks (Â±3 days) and there must be at 
least [ADDRESS_184683] (ur
ine or serum) is required for female participants of childbearing potential at Screening and pri or to each do
se of study drug (see  Appendix  8 
for information
 regarding pregnancy follow -up). 
4 Results from the 
hematology panel should be evaluated prior to study drug administration. For C1D1 and C2D22 visits, blood sa mples should be ta
ken and 
assessed for Hgb
 levels on the same day as study drug administration.  For all other dosing cycles , blood samples m
ay be taken and assessed for Hgb levels on 
the same day as stud
y drug administration or 1 day prior to dosing. If Hgb is â‰¥  17.0 g/dL during C
ycles 1 and 2, participant should return weekly for Hgb 
monitoring (and
 continue to follow Dose Mo dification Guidance 
for dosing days [ Section  6.3]). 
5 Additional screening
 procedures to include pulmonary function tests and VQ/CT pulmonary angiogram (CTPA) or pulmonary angiogr aphy as per inclu
sion 
criteria 5 and 6 (Section  5.1), if historical rea
dings are unavailable.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184684] 2021 
Acceleron Pharma Inc.  Page 15 of 93 CONFIDENTIAL  6 Cardiac MR and iCPET  may be done o
n separate days.  If performed on the same day, iCPET should be performed before cardiac MR, with â‰¥ 1-hour interval 
between procedu
res. 
7 6MWT: to be perfo
rmed twice during the Scre ening Period a
t least 4 hours (but no longer than 1 week) apart and distances must be within 15% of each other, 
calculated from th
e higher number.  
8 RHC with CPET (
iCPET) to be completed within 10 days prior to Cycle 1, Day 1.  A participant will not recei ve more than 3
 iCPET assessments dur
ing the 
study.  If 
other assessments are occurring on the same day, iCPET should be performed after all other procedures (Exception: cardiac MR).  
[ADDRESS_184685] be done prior to admini stration of stu
dy drug.  Dosing: The dose must be calculated based on the participantâ€™s 
weight on the day
 of dosing. Dose -modification guid
elines must be reviewed and implemented prior to dosing as required per protocol (see Section  6.3). 
11 AEs and SAEs occur
ring after the signing of the informed consent form and before Cycle 1, Day 1 will be reported and document ed on the AE eCR
F.  If 
related to prot ocol procedur
es (S)AEs should be indicated as such in the eCRF.
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184686] 2021 
Acceleron Pharma Inc.  Page 16 of 93 CONFIDENTIAL  Table  4: Schedule of Events: Exte
nsion and Follow -Up Periods  
 Extension Peri
od (18 Months)1  Follow -Up Period (8 We
eks) 
Cycle 10  Cycles  
11-13 Cycle  
14 Cycles  
15-16,  
18-20, 22 -24, 
26-28, 30 -33 Cycle 
17 Cycles  
21, 25, 29, 
342 End of Treatme
nt11 
At time of ear
ly 
discontinuatio
n or 4  weeks 
(Â±7 days) post last 
dose of 
study drug  End of Study  
8 weeks (Â±7 days)
 post last 
dose of study dr
ug 
Â±3 days  Â±3 days  Â±3 days  Â±3 days  Â±3 days  Â±3 days  (Â±7 days)  (Â±7 days)  
Physical exami
nation2 X X X X X X X X 
Vital signs (in
cluding 
weight)  X X X X X X X X 
Pregnancy test3 X X X X X X   
Hematology4 X X X X X X X X 
Serum chemistry  X  X  X X X X 
Urinalysis  X  X  X X X X 
12-lead ECG  X  X   X X X X 
Anti-drug antibody
 (ADA) 5 X  X   X  X 
Cardiac MR6     X    
6MWT  X  X  X X X X 
RHC + CPET (iCP
ET) 6,7     X    
Transpulmonary
 flux 
biomarkers8     X    
WHO Functiona
l Class 
Assessment  X X X X X X X X 
Clinical worse
ning X X X X X X X X 
PD blood biomark
ers X  X   X  X 
Study drug ad
ministration9 X X X X X X   
AE/SAE review10 X X X X X X X X 
Concomitant me
dication 
review  X X X X X X X X 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184687] 2021 
Acceleron Pharma Inc.  Page 17 of 93 CONFIDENTIAL  Abbreviations: 6MWT  = 6-minute walk test; ADA  = anti-drug antibody
; AE  = adverse event; CPET
 = cardiopulmonary exercise test; ECG  = electrocardiogra
m; 
eCRF  = electronic case rep
ort form; EOT  = end of treatm
ent; Hgb  = hemoglobin; iCPET  = invasive cardiopu
lmonary exercise tes
t; MR  = magnetic resonance; 
PD = pharmacody
namics; RHC  = right heart catheterizatio
n; SAE  = serious advers
e event; WHO  = World Health Org
anization.  
1 All visit day windows sh
ould be considered relative to the date of the previous dose of study drug. Cycles are every 21 days (Â±3 days).  
[ADDRESS_184688] (urine or 
serum) is required for female participants of childbearing potential prior to each dose of study drug (see  Appendix  8 for pregna
ncy 
follow-up). 
[ADDRESS_184689] es may be taken an
d assessed for 
Hgb levels on the 
same day as study drug administration or 1 day prior to dosing.  If Hgb is â‰¥ 17. 0 g/dL, particip
ants should return weekly for Hgb monitoring 
(and continue to
 follow Dose Modification guidance for d
osing days [ Section  6.3]). 
5 If a participant has a po
sitive ADA result at the EOT assessment, the participant may be asked to return approximately every 3 mon ths for ad
ditional testing, 
until a negative result is
 obtained or the result is considered stabilized.  
6 Cardiac MR and iCPET
 may be done on s
eparate days.  If performed on the same day, iCPET should be performed before cardiac MR, with â‰¥ [ADDRESS_184690] 
occur within 10
 days prior to Cycle 1 (during the Screening Period), and within 10 days prior to Cycle 9 (during treatment pe riod), and C
ycle 14 during the 
Extension Period
.  For patients discontinuing the study  prior to Cycle 
9, an iCPET  should be per
formed Â± [ADDRESS_184691] iCPET is to be 
performed at th
e time of early discontinuation if prior to Cycle  14.  If oth
er assessments are occurring on the same day, the iCPET should be performed af ter all 
other procedu
res (Exception:  cardiac MR  imaging ). 
[ADDRESS_184692] be calculated based on the participantâ€™s wei ght on the day 
of dosing. Dose 
modification Guid
ance must be reviewed and implemented prior to dosing ( Section 6.3). 
10 AEs and SAEs occur
ring after the signing of the informed consent form will be reported and documented on the AE eCRF.  If rel ated to protocol 
procedures, 
(S)AEs should b
e indicated as such in the eCRF.  
[ADDRESS_184693] iCPET and consent to the sotate rcept  long-term follow -up study  will be asked to com
plete the EOT Visit only. 
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184694]  2021 
Acceleron Pharma Inc.  Page 18 of 93 CONFIDENTIAL  3. INTRODUCTION  
Pulmonary arterial hypertension (PAH) re
presents a group of diseases causing a progressive 
increase in pulmonary vasc ular resistance (PVR), resulting i
n right ventricular dysfunction and 
ultimately failure as well
 as premature death.3,4  PAH pathophysiology involves pulmonary 
endothelial dysfunction, resulting in impaire
d production of vasodilators, such as nitric oxide and 
prostacyclin, and overexpr ession of vasoconstrictors, such a
s endothelin -1.  The pathophysiology 
of PAH also entails the abnormal prolifera
tion of pulmonary vascular smooth muscle cells 
(VSMCs) in pulmonary arterioles, which r
esults in progressive pulmonary vascular remodeling, 
increased pulmonary vascular
 resistance and, eventually, right -sided heart failure .5  In the 
absence of treatme
nt, th e majority of patients succ
umb to heart failure within a few years of 
diagnosis.6  There is currently no pharmacol ogical cure for  PAH; treatment involve
s relieving 
symptoms by [CONTACT_159088].  Current 
disease -specific treatments  for PAH include vasodilator -type agents such as endothelin -receptor 
antagonists (ERAs), phosphodiesterase type 5 (PD
E5) inhibitors, and prostanoids and are used to 
supplement general supportive ca
re agents (e.g., anticoagulants, diuretics, digoxin).  
Gene tic mutations in the bone morphogenetic p
rotein type II receptor (BMPR2) are associated 
with the majority of the familia
l forms of PAH7,8 and approximately 25% of idiopathi
c PAH.  
Specifically, impairment 
of the BMPR2 -associated  signal pathway appears to lead to 
uncontrolled proliferation of
 pulmonary VSMCs.  These data strongly suggest a key role of 
transforming growth factor -beta (TGF -Î²) superfamily members in the pa
thogenesis of PAH.  
Sotatercept (ACE -011) is a first -in-class human fusion protein consisting of the extrace
llular 
domain of the activin receptor type IIA
 (ActRIIA) linked to the Fc domain of human 
immunoglobulin G1 (IgG1).  Sotaterc
ept works by [CONTACT_159089] -Î² 
superfamily, which includes acti
vins, g rowth and differentiation fa
ctors (GDFs), and BMPs.  
Sotatercept may improve pulmona
ry vascular remodeling by [CONTACT_159090].8 
3.1. Study Rationale  
Study A011 -10 is a Phase 2a, single -arm, open -label, multicenter exploratory study to dete
rmine 
the effects of sotatercept 
(ACE -011) in adults with World Health Organiz
ation (WHO) Group 1 
PAH.  
This study is designed to evaluate whether sot
atercept has the potential to modify the clinical 
course of PAH, as assessed by [CONTACT_159091] (iCPET), various imaging parameters collected via cardiac 
magnetic resonance (MR) imaging, a
nd correlation with  other functional measures a
nd 
assessments of clinical worsening.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184695]  2021 
Acceleron Pharma Inc.  Page 19 of 93 CONFIDENTIAL  3.2. Rationale for 
Patient Population  
Patients with WHO Group 1 pulmona
ry hypertension (i.e., PAH associated with idiopathic, 
heritable, drug -induced, connective ti
ssue diseases, or post -shunt co rrection) and meet the W
HO 
functional assessment definition for Class I
II PAH will be the population studied.  
The WHO Functional Cl
assification9 (FC) is based on an assessment of the degre
e of physical 
activity limitation due primaril
y to associated dyspnea:  
â€¢ FC I: Patients with pul
monary hypertension but without resulting limitation of 
physical activity.  Ordinary ph ysical activity does not cause undue dyspn
ea or fatigue, 
chest pain or near syncope.  
â€¢ FC II: Patients with pul
monary hypertension resulting in a slight limitation of 
physical activity.  They are c
omfortable at rest.  Ordinary physical activity causes 
undue dyspnea or fatigue, chest pain or nea
r syncope.  
â€¢ FC III: Patients wi
th pulmonary hypertension resulting in marked limitation of 
physical activity.  They are c
omfortable at rest.  Less than ordinary activity causes 
undue dyspnea or fatigue, chest pain or ne
ar syncope.  
â€¢ FC IV: Patients with pul
monary hypertension with inability to carry out any physical 
activity without symptoms.  These pati
ents manifest signs of right heart failure. 
Dyspnea and/or fatigue may eve
n be present at rest.  Discomfort is increased b y any 
physical activity.   
Previously diagnosed patients i
n FC I, II, III, and IV had an estimated 5 -year survival rate of 
88.0%, 75.6%, 57.0%, and 27.2%, respecti
vely, compared with 72.2%, 71.7%, 60.0%, and 
43.8% for newly diagnosed patients in FC
 I, II, I II, and IV, respective
ly.[ADDRESS_184696] may be more ch
allenging 
to ascertain compared with functi
onal class III PAH patients.  There is a relatively low 
prevalence of patients wi
th class IV PAH due to higher mortality and transplant rates compared 
with other functional classes; gi
ven their  severe disease burde
n, these class IV patients have 
limited ability to participa
te in longer interventional studies.  Eligibility criteria for this study are 
consistent with those of other interventiona
l studies in this population.  
3.3. Rationale for Stu
dy End points  
The primary endpoint of the study is the change f
rom baseline in peak oxygen  uptake 
(VO 2 max), as measured by [CONTACT_159092] (CPET).  This endpoint was chosen 
because of the importance
 of VO [ADDRESS_184697] organic causes of 
exertional dyspnea involves insufficient O 2 supply to 
skeletal muscle or impaired uptake
 of O 2 by [CONTACT_159093] e cells, which, collec
tively, may be 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184698]  2021 
Acceleron Pharma Inc.  Page 20 of 93 CONFIDENTIAL  attributable to abnormal cardiac
, pulmonary vascular, or neuromuscular function.  The integrated 
function of these systems is broadly assessed by m
easuring the peak oxygen uptake ( VÌ‡O2), 
which is calculated as the produ ct of minute ventilation (VE) and the differ
ence in inspi[INVESTIGATOR_159064] O 2.  Thus, a fundamental objective
 of noninvasive (or invasive) CPET is 
quantification of maximum VO 2, which is considered abnormal when <  80% of predicted for the 
patien tâ€™s age, gender, and height .10 
In a study of patients with W
HO Group 2 pulmonary hypertension and systolic heart failure 
(mean [standard deviation (SD)
] age 58 [13] years; depressed left ventricular [LV] ejection 
fraction [EF] 0.27 [Â±0.05]; a
nd VO 2 max 11.2 [Â±3.2] mL/kg/min), the patients underw
ent 
incremental CPET with simultane
ous hemodynamic monitoring and first -pass radionuclide 
ventriculography before and a
fter 12 weeks of treatment with sildenafil, a selective pulmonary 
vasodilator, or placebo.  Silde
nafil was associated with an approximate 28% decrease in 
pulmonary vascular resistance
 (PVR), an approximate 10% increase in VO 2 and an approximate 
10% decrease in VE/VC
O2.11 
An important CPET secondary endpoint is chang
e from baseline in ventilatory effici
ency 
(VE/VCO 2) slope.  If, as predicted by [CONTACT_159094], treatment with sotatercept 
results in modification of pulmonary va
scular wall architecture, improvement in right -sided lung 
perfusion pressures, and r eduction in right heart mecha
nics, then gas exchange efficiency should 
be improved.  This should result in an improved oxygen uptake
 rate VO 2, as well as a reduction 
in pulmonary dead space and a
n improved ventilatory efficiency (as measured by [CONTACT_128466]/VCO 2). 
Another important secondary endpoint is chang
e in right ventricular (RV) stroke volume (SV) at 
[ADDRESS_184699] of sotatercept on RV function.  
Given the pi[INVESTIGATOR_159065] m orbidity and mortality of 
PAH, a significant improvement in RV f
unction on cardiac MR imaging could demonstrate that 
the clinical course of the subjec
tâ€™s PAH has been meaningfully improved.  Cardiac MR imaging 
is particularly suitable for acc
urately assess ing the anatomical structure
 as well as function of the 
RV, and it is regarded as the gold st
andard test for quantifying ventricular volume, mass, 
structure, and function.  It is non -invasive, and does not involve the use of ioniz
ing radiation.  
Cardiac MR  imaging provides high -resolution, 3 -dimensional images that avoid the ne
ed for the 
geometrical assumptions required for some c
alculations when using echocardiography.  
However, cardiac MR ima
ging is also associated with the following range of limitations:  higher 
cost, more limited availabil
ity relative to other methods, the need for more intensive and 
time-consuming analysis, and the requirement f
or significant technical support and expertise.  In 
addition, cardiac MR imaging is incompa
tible with pacemaker s and infusion pumps, and the 
need for breath holding may be diff
icult for PAH patients.  However, given the relevance of the 
right heart in PAH, the advantages of the me
thod outweigh these disadvantages in the monitoring 
of patients with established PAH a nd in assessment of treatment response
 in clinical trials.  The 
clinical relevance of c
ardiac MR imaging in PAH was demonstrated in a study of [ADDRESS_184700] -of-care (SOC) therapy on cardia
c MR 
imaging asses sments of changes in stroke volume and c
orrelating them with concurrent changes 
in 6-minute walk distance (6MWD), a f
requently used measure of activity/function in PAH 
patients.  The study found that an improvement in RV  SV of as little as 10 mL was 
progno stically significant and corre
lated with a meaningful improvement in 6MWD in PAH 
patients.12 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184701]  2021 
Acceleron Pharma Inc.  Page 21 of 93 CONFIDENTIAL  In addition, assessm ent of RV SV may correlate with other
 functional and physiologic measures 
commonly assessed in treated PAH patients (e
.g., cardiac index, mean pulmonary arterial 
pressure [PAP], VO 2 max, Ca -vO2, VE/VCO 2 slope, PVR, and N -terminal prohormone of brain 
natriu retic peptide [NT -proBNP]).  
Other secondary endpoints in this study 
include change in RV end -systolic volume (ESV), 
RV end-diastolic volume (EDV), change in RV E
F, change in RV stroke volume index (SVI), 
change in RV mass by [CONTACT_159095] 24 weeks  from baseline, iCPET result
s for 
exercise hemodynamic measure
s (including change in cardiac index, mean PAP, Ca -vO2 
[arteriovenous O 2 content difference], 
VE/VCO 2 slope [ventilatory efficiency], e
valuation of 
changes in PVR, changes in 6MWD
, clinical wors ening (including changes in WHO func
tional 
class assessment and hospi[INVESTIGATOR_159066]), pharmacokinetic (PK) results, pharmacodynamic (PD) 
results, and safety.  With the modific
ation of pulmonary vessel wall architecture and pulmonary 
vessel pressure and paten
cy, it is hypothesized that improvements in RV perfor
mance and 
structural measures, arte
riovenous oxygen differences, ventilatory efficiency, and pulmonary 
vascular resistance will
 result.  The relevant downstream clinical benefits of these improvements 
should also include improvement in 6MWD and quality of li
fe and reduction in clinical 
worsening events.  Of note, 6MWD and cha
nge in WHO functional class are predictors of 
mortality in PAH .1,13,14  Safety will be assessed by [CONTACT_159096] (AEs) and 
laboratory results, which will be grade
d for severity using the current version of the National 
Cancer Institute -Common Terminology Criteria for A
dverse Events (NCI -CTCAE).  
3.4. Rationale for 
Dose Level and Frequency Selection  
3.4.1.  Treatment Period  
A dose regimen of 0.3 mg/kg sotater
cept SC for Cycle 1 and escalating to 0.7 mg/kg at Cyc le 2 
SC every 3 weeks (Q3W
) was selected after reviewing all relevant PK, safety, and efficacy data 
for sotatercept.  Based on
 population PK/PD modeling of data from a Phase 1 healthy volunteer 
study, exposure modeling of sotatercept from prec
linical model s of PAH, and tÂ½ of sotatercept 
(~23 days), Q3W dosing is expec
ted to result in the maintenance of target drug levels in patients 
with PAH.  See  Section  4.10.  
3.4.2.  Extension Period  
In the 18 -month Extension Period, a dose regimen of e
very 3 weeks (Q3W) will be evaluated. 
Comparable dose levels based on exposure -matching will be selected to maintain steady -state 
exposures through the Extension Period.  
3.5. Background  
PAH applies to a group of disease
s causing a progressive increase in PVR, resulting in RV 
dysfunction and ultimately failure
 as well as premature death.3,4  PAH pathophysiology involves 
pulmonary endothelial dysfunction,  resulting in impaired production of
 vasodilators, such as 
nitric oxide and prostacyclin, and ove
rexpression of vasoconstrictors, such as endothelin -1.  The 
pathophysiology of PAH also entails the a
bnormal proliferation of pulmonary VSMCs in 
pulmonary arte rioles, which results in progressi
ve pulmonary vascular remodeling, increased 
PVR and, progressive, right -sided heart failure .5  In the absence of trea
tment, the majority of 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184702]  2021 
Acceleron Pharma Inc.  Page 22 of 93 CONFIDENTIAL  patients succumb to heart
 failure within a few years of diagnosis.6  There is currently no 
pharmacological cure for  PAH; treatment involves re
lieving symptoms, principally by [CONTACT_159097] h 1 or more vasodilators and slowing clinica
l 
worsening of the disease.  Curre
nt disease -specific treatments for P
AH include vasodilator -type 
agents such as endothelin -receptor antagonists (ERAs), phosphodiester
ase 5 (PDE5) inhibitors, 
and prostanoids, whi ch are used to supplement general supp
ortive care agents (e.g., 
anticoagulants, diuretics, digoxi
n).  Recent preclinical data sugge
st that sotatercept (murine 
analogue, RAP -011) may positively affect vasc
ular remodel ling in animal models of PAH .[ADDRESS_184703] 
vascular remodel ling.2 
A detailed description of the chemistry, pharma
cology, efficacy, and safety of sotatercept  is 
provided in the Investigatorâ€™s B
rochure (IB).  
3.6. Benefit/Risk Asse
ssment  
The study will be conducted in participants who re
quire treatment for the management of PAH. 
The study design, inclusion/exclusion criteria
, and procedures have been developed in a manner 
to protect participant safety.  
The evidence for potential bene
fits comes from data observed in rodent models of PAH.  These 
potential clinical benefits include reduced mus
cularization and thickness of pulmonary vessel 
walls, reduced r ight-sided heart pressures, and red
uced right -to-left ventricle weight ratios.2  
These clinical improvements m
ight be accompanied by [CONTACT_159098], which will also be measured 
during the study.  
Possible risks to participants observed in prior 
clinical studies with sotatercept inclu de increases 
in hemoglobin (Hgb), hematocrit, red blood cell (RB
C) count, and blood pressure (BP).  These 
will be diligently monitored and mana
ged during the study, and interruption or adjustments of 
dosing as necessary (in addition t
o medical treatment) t o ameliorate these risks.  Potential risks 
of development of anti -drug antibodies (ADAs), reproduc
tive effects, and renal injury, though 
not seen in clinical studies of sotaterc
ept but observed in some preclinical studies, will also be 
monitored.  Thorough  monitoring of all AEs experienced by 
[CONTACT_159099].  
In prior sotatercept clinic
al oncology studies in chemotherapy -induced anemia and ost
eolytic 
bone disease in multiple myeloma, the following have
 been described as t reatment -emergent 
adverse events (TEAEs): leukope
nia, neutropenia (including febrile neutropenia), 
granulocytopenia, and thrombocytopenia.  As a result
 of the decrease in white blood cells and 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184704]  in this study (see  Section  6.3 Dose Modification and 
Section  8.3 Adverse Events).  
More detailed information about the known and e
xpected bene fits and risks and possible AEs of 
sotatercept can be found in t
he IB.  
Table  5 indicates the objectives and endpoints of the study
.   
Table  5: Objectives and Endpo
ints 
Objectives  Endpoints  
Primary  
â€¢ To evaluate the effec
t of sotatercept  on an 
invasive cardiopulm
onary exercise test 
(iCPET) measure 
in PAH patients treated 
with sotatercept plus 
standard of care 
(SOC)  â€¢ Change from b
aseline in VO 2 max at 24  weeks  
Secondary  
â€¢ To evaluate the effec
t of sotatercept on 
additional iCPET meas
ures i n PAH patients 
treated with sotatercep
t plus SOC  â€¢ Exercise measures, inclu
ding change in 
VE/VCO 2 slope (ventilatory 
efficiency), cardiac 
index, mean pu
lmonary arterial pressure, Ca -vO 2 
(arteriovenous O 2 content difference)
 at 24 
weeks  
â€¢ To evaluate effects 
of sotatercept on right 
ventricular stroke 
volume (RV  SV), 
RV end-systolic volume (
RV ESV), 
RV end-diastolic volume (R
V EDV), 
RV ejection fraction (
RV EF), RV stroke 
volume index (R
V SVI), and RV mass
 by 
[CONTACT_159100]
t plus SOC  â€¢ Change from b
aseline in RV SV, RV ESV, 
RV EDV, RV EF, RV SVI,
 and RV mass by 
[CONTACT_159101] (MR) imaging  at 
24 weeks  
â€¢ To evaluate the effec
t of sotatercept on 
pulmonary vascu
lar resistance (PVR) in 
PAH patients treated with 
sotatercept plus 
SOC  â€¢ Change from b
aseline in PVR at 24 weeks  
â€¢ To assess the PK of sotatercept in PAH 
patients treated with s
otatercept plus SOC  â€¢ Population PK parameter
s of sotatercept  
â€¢ To evaluate the effec
t of sotatercept on 
6-minute walk distance 
(6MWD) in PAH 
patients treated with s
otatercept plus SOC  â€¢ Change from baseline in 6MWD at 24 weeks  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184705]  2021 
Acceleron Pharma Inc.  Page 24 of 93 CONFIDENTIAL  Table  5: Objectives and Endpoints (Continued)  
Objectives  Endpoints  
â€¢ To evaluate the effect of sotatercept on PD 
biomarker(s)  in PAH patients treated with 
sotatercept plus SOC  â€¢ Change from baseline in NT -proBNP  at 
24 weeks  
â€¢ Change from baseline in WHO functional class 
at 24  weeks  
â€¢ To assess the safety and tolerability of 
sotatercept in PAH patients treated with 
sotatercept plus SOC  â€¢ Clinical worsening (e.g., hospi[INVESTIGATOR_602], change 
in WHO functional class)  
â€¢ Occurrence of adverse events  
Exploratory  
â€¢ To assess additional biomarkers  in PAH 
patients treated with sotatercept plus SOC  â€¢ Change from baseline in PAH -related 
biomarkers  
â€¢ To evaluate the primary and secondary 
endpoints during the Extension Period in 
PAH patients treated with sotatercept plus 
SOC  â€¢ Change in selected primary and secondary 
endpoints during the Extension Period  
â€¢ Exercise hemodynamic measures  in PAH 
patients trea ted with sotatercept plus SOC  â€¢ RV-pulmonary arterial (PA) coupling ratio 
(based on single beat assessment), VO 2 at 
anaerobic threshold (O 2 consumption at 
anaerobic threshold), heart rate recovery 
(> 12 beats at 1 minute recovery), exercise 
oscillatory venti lation (present or absent as 
defined by [CONTACT_159102]), 
distensibility, resting and peak exercise end tidal 
CO 2 
6MWD  = 6-minute walk distance; AHA  = American Heart Association; Ca -vO 2 = arteriovenous O 2 content 
difference; iCPET  = invasive cardi opulmonary exercise test; MR  = magnetic resonance; NT -proBNP  = N-terminal 
prohormone of brain natriuretic peptide; PA  = pulmonary arterial; PAH  = pulmonary arterial hypertension; 
PD = pharmacodynamic; PK  = pharmacokinetics; PVR  = pulmonary vascular resista nce; RV = right ventricular; RV 
EDV  = right ventricular end -diastolic volume; RV EF  = right ventricular ejection fraction; RV ESV  = right 
ventricular end -systolic volume; RV SV  = right ventricular stroke volume; RV  SVI = right ventricular stroke 
volume ind ex; SOC  = standard of care; VE/VCO 2 = ventilator efficiency; VO 2 max = peak oxygen uptake; 
WHO  = World Health Organization.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184706] of Care  
In the Treatment Period, 
SOC therapy refers to combination therapy consisting of  drugs from 
two or more of the  following drug classes: an  ERA, a PDE5 inhibitor, a soluble guanylate
 
cyclase stimulator, and/or a prosta
cyclin analogue or receptor agonist.  Small adjustments or 
titrations are routine SOC for PAH
 therapi[INVESTIGATOR_159067].  Patients rec eiving 
monotherapy are not to be enrolle
d.  The SOC details can be found in Appendix  3. 
During the Extension Period, parti
cipants under investigatorâ€™s supervision can substitute, 
remove, or adjust the dose of SOC for PAH -worsening and chronic concomita
nt medications, 
including supplemental oxygen.   Investigator discretion will be use
d to determine if sotatercept 
study drug discontinuation is necessar
y. 
4.4. Screening Period  
Upon giving written informed consent, participants will
 enter the Screening Period to determine 
eligibility.  Participant scree
ning procedures are to take place within  [ADDRESS_184707] dose 
of study drug.  During the Screening Pe
riod, participants will undergo assessments t
o determine 
eligibility for the study and to obtain baseli
ne measurements, including cardiac MR
 imaging 
parameters.  Right heart catheteri
zation (RHC) for assessment of baseline CPET, PVR, 
pulmonary capi[INVESTIGATOR_159068] (PCWP), and right -sided heart pressures is to be comple
ted 
within [ADDRESS_184708] of care plus a starting dose of sotatercept 
0.3 mg/kg subcutaneous ly (SC) for Cycle 1 and esca
late to 0.7 mg/kg SC at Cycle [ADDRESS_184709] not discontinue
d early from the 24 -week Treatment Pe
riod may continue  
to an 18 -month Extension Period.  Part icipants will continue to receive sot
atercept at c omparable 
dose levels, based on exposure -matching, to maintain steady -state exposures through the 
Extension Period, plus SOC.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184710] dose of study treatment 
during the Extension Period.   
Participants who discontinue early, including during the 24 -week Treatment Period or  the 
18-month Extension Period , will be asked to return for End -of-Treatment (EOT ) and 
End-of-Study (EOS ) visits. 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184711] 2021 
Acceleron Pharma Inc.  Page 27 of 93 CONFIDENTIAL  Figure  1: Study Design  
 
6MWT = [ADDRESS_184712]; EOS =
 end of study; EOT = end of treatment; iCPET  = invasive card
iopulmonary exercise test; MR = magnetic resonance; 
PD = pharmacodynam
ic; PK = pharmacokinetic; SC = subcutaneously ; SOC = standard o
f care.  
Refer to Section [ADDRESS_184713] of study proce
dures/assessments.  
 
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184714] 2021 
Acceleron Pharma Inc.  Page 28 of 93 CONFIDENTIAL  4.8. Participant and Stu
dy Completion  
Approximately 25 participants will re
ceive SOC plus sotatercept at a starting dose level of 
0.3 mg/kg for Cycle 1 and then 0.7  mg/kg at Cycle [ADDRESS_184715] c
ompleted the study if he/she has completed all periods of the 
study, including the EOT and EOS  visits.  
End of Study visits are only required for pa
rticipants who di scontinue the study early  or decline 
transition to a future sotaterc
ept long -term follow -up study.  The End of Study is defined as 
when the last participant completes the last visit.  
4.10. Justification f
or Dose  
Selection of the dose and dosing frequency are bas
ed on data from studies in healthy volunteers 
and patients with other chronic disea
ses.  In 2 completed Phase 1 studies ( Studies  A011 -01 and 
A011 -02), single doses of sotatercept up to 3.0 mg/kg intra
venous (IV) and multiple doses of 
sotat ercept up to 1.0 mg/kg SC were ge
nerally well tolerated in healthy postmenopausal women. 
Consistent with observations from nonclinica
l safety studies, many of the observed PD effects in 
the Phase 1 clinical studies were a
ttributable to the expected biologi c activity of activin 
inhibition (e.g., dose -dependent decreases in circ
ulating follicle -stimulating hormone [FSH], a
nd 
transient, reversible effects on red blood cell [ RBC ] parameters such as Hgb).  Using data f
rom 
the Phase 1 studies, a PK/PD model for H gb as a surrogate marker for tar
get engagement was 
developed.  Simulations from this model also showed that the probabil
ity of having Hgb 
â‰¥ 18 g/dL and an increase in Hgb â‰¥ 2 g/dL is highe
r during the first 3 weeks after a dose
 of 
0.7 mg/kg than after a do se of 0.3 mg/kg.  Therefore, a starti
ng dose level of 0.3 mg/kg was 
selected for Cycle 1 and a dose leve
l of 0.7 mg/kg was selected at Cycle [ADDRESS_184716] that this dosing re
gimen may 
reduce the number of partic
ipants with increase in Hgb â‰¥ 2 g/dL.  
Based on the PK model developed from the Phase 1 data, the
 projected mean C trough level at 
steady state is 8.1 Î¼g/mL at this dose a
nd frequency.  This projected exposure is similar to the 
Cmax after the first dose of 1.0 mg/kg (7
.4 Î¼g/mL) in Study A011 -02.  At the planned dose and 
frequency in this study, the proje
cted C max and AUC 21d are 12.4 Î¼g/mL and 217 day*Î¼g/mL, 
respectively.  
The risk of AEs due to Hgb increase
 will be ameliorated by [CONTACT_159103], 
delay, and stoppi[INVESTIGATOR_159069] ( Section 6.3). 
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184717] of 
Clinical Trials of Medical Products during COVID -19 Pandemic Gu idance for Industry, 
Investigators, and Institutional R
eview Boards; March 2020 ( FDA 2020 )18.  
5.1. Inclusion Criteria  
Participants must satisfy all of the following criteria to be enrolled in the study:  
1.Age â‰¥ 18 years
2.Documented findings on right heart catheterization (RHC ) at any time prior to Screening
consistent with a diagnosis of WHO pulmonary hyperte
nsion Group 1: PAH of any of the
following subtypes:
âˆ’Idiopathic PAH
âˆ’Heritable PAH
âˆ’Drug - or toxin -induced PAH
âˆ’PAH associated with connecti
ve tissue disease
âˆ’PAH associated with simple, conge
nital systemic -to-pulmonary shunts at least
1 year following shunt repair
3.Symptomatic pulmonary hypertension classified as WHO functional c
lass III
4.Screening Period RHC (within 10 days prior
 to C1D1 visit) documenting a minimum
PVR of â‰¥ 4 Wood units
5.Pulmonary function tests  within 6 months prior to Screening as follows:
a.Total lung capacity > 70% pre
dicted; or if between 60% to 70% predicted, or not
possible to be determined, confirmatory high -resolution computed tomography (CT)
indicating no more than mild interstiti
al lung disease per investigator interpretation;
or,
b.Forced expi[INVESTIGATOR_12194] (first second
) (FEV 1)/forced vital capacity (
FVC)  > 70%
predicted
c.For subjects with a history of lobectomy or p
neumonectomy, and for whom there are
no population -based normalization methods, assessment based on r
esidual lung
volume will be permitted to assess eligibilit
y.
6.Vent ilation -perfusion (VQ) scan (or, if unav
ailable, a negative CT pulmonary angiogram
[CTPA] or pulmonary angiography result
), any time prior to Screening or conducted
during the Screening Period, with normal or low proba
bility result
7.6MWD â‰¥ 100 and â‰¤ 550 meters repeated twice during Sc
reening Period and both values
within 15% of each other, calcula
ted from the highest value (see  Appendix  4)
8.Combination PAH  therapy at stable (per SOC) dose levels as de
fined in Section  4.[ADDRESS_184718] 90 days prior to Cycle 1 Day 1 (C1D1)
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184719] 2021 
Acceleron Pharma Inc.  Page 30 of 93 CONFIDENTIAL  9. Females of childbearing potenti
al (defined in Appendix  8) must:  
a. Have [ADDRESS_184720] u
sed, and agree to continue to use, h ighly effective 
contraception** without interruption, for at lea
st [ADDRESS_184721] (IP), during the study
 (including dose interruptions), and for 
16 weeks (112 days) after discontinuati
on of study treatment.  
c. Refrain from b reastfeeding a child or d
onating blood, eggs, or ovum for the duration 
of the study and for at least [ADDRESS_184722] dose of study treatment.  
** (see Appendix  8 for additional contraceptive
 information ) 
10. Male participants must:  
a. Agree to use a condom, de
fined as a male latex condom or nonlatex condom NOT 
made out of  natural (animal) membrane 
(for example, polyurethane), during sexual 
contact [CONTACT_4490] a pregnant female
 or a female of childbearing potential while 
participating in the study, during dose interruptions, a
nd for at least 112 days 
following IP discontinuation, even if he has undergone a suc
cessful vasectomy. 
(see Appendix  8 for additional contraceptive infor
mation)  
b. Refrain from donating sperm f
or the duration of the study and for [ADDRESS_184723] dose of study treatment.   
11. Ability to adhere to the study visit sche
dule and understand and comply with all protocol 
requirements  
12. Ability to understand and provide written informed c
onsent  
5.2. Exclusion Crit eria 
Participants will be excluded from t
he study if they meet any of the following criteria:  
1. Started or stopped receiving any ge
neral supportive therapy for pulmonary hypertension 
(e.g.,  diuretics, oxygen, anticoagulants, di
goxin) within 60 days prior to C1D1  
2. Received IV inotropes (e.g., dobutamine, dopa
mine, norepi[INVESTIGATOR_238], vasopressin) within 
30 days prior to C1D1  
3. History of atrial septostomy within 180 days prior to Sc
reening Visit  
4. History of more than mild obstructive slee
p apnea that is untreated  
5. History of portal hypertension or chronic liver dis
ease, defined as mild to severe hepatic 
impairment (Child -Pugh Classes A to C)  
6. History of human immunodeficiency virus infe
ction -associated PAH  
7. Prior exposure to sotatercept (A
CE-011) or luspatercept (ACE -536) 
8. Initiation of an exercise progr
am for cardiopulmonary rehabilitation within 90 days prior 
to C1D1 or planned initiation during the
 study (participants who are stable in the 
maintenance phase of a progr
am and who will continue for the duration of the study  are 
eligible)  
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184724] 2021 
Acceleron Pharma Inc.  Page 31 of 93 CONFIDENTIAL  9.Uncontrolled systemic hypertension as evidenced by [CONTACT_159104] >  160 mm Hg or
sitting diastolic BP > [ADDRESS_184725]
10.Systolic BP < 90 mm Hg during Screening Visit or at baseline (C1D1)
11.History of known pericardial constriction
12.RHC contraindicated during the study per investigator
13.Electrocardiogram (ECG) with QTcF >  480 msec during Screening or C1D1
14.Personal or family history of long QTc syndrome or sudden cardiac death
15.Cerebrovascular accident w ithin 3 months of C1D1
16.History of restrictive or constrictive cardiomyopathy
17.Left ventricular ejection fraction < 45% on historical ec hocardiogram performed within
6 months prior to Screening Period (or done as a part of the Screening Period) or PCWP
> 15 mmHg as determined in the Screening Period RHC
18.Any current symptomatic coronary disease (myocardial infarction, percutaneous coronary
intervention, coronary artery by[CONTACT_10956], or cardiac anginal chest pain in the
past 6 months prior to Screening Visit)
19.Acutely decompensated heart failure within 30 days prior to C1D1, as per investigator
assessment
20.Significant (â‰¥  2+ regurgitation) mitral regurgitation or aortic regurgitation valvular
disease
21.Any of the following clinical laboratory values during th e Screening Period prior to
C1D1:
a.Baseline Hgb > 16.0 g/dL within 28 days of C1D1
b.Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels
>3 ï‚´ upper limit of normal (ULN) or total bilirubin > 1.5 ï‚´ ULN within 28  days of
C1D1
c.Estimated glomerular filtration rate <  30 mL/min/1.73  m2 (4-variable Modification of
Diet in Renal Disease equation) within 28 days of C1D1 or required renal
replacement the rapy within 90 days
22.History of opportunistic infection (e.g., invasive candidiasis or Pneumocystis  pneumonia)
within 6 months prior to Screening; serious local infection (e.g., cellulitis, abscess) or
systemic infection (e.g., septicemia) within [ADDRESS_184726] completely
recovered from any previous surgery prior to  C1D1
25.Prior heart or heart -lung transplants or life expectancy of < 12 months
26.Pregnant or breastfeeding females
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184727] 2021 
Acceleron Pharma Inc.  Page 32 of 93 CONFIDENTIAL  27.At any time in the 30 days prior to the Screening Period received > 20 mg/day of
prednisone (or  equivalent) or started or changed the dose of a systemic corticosteroid.
Participants receiving stable doses of â‰¤ 20 mg prednisone (or equivalent) in 30 days prior
to the Screening Period are permitted in the study.
28.History of active malignancy, with the exception of fully excised or treated basal cell
carcinoma, cervical carcinoma in -situ, or â‰¤  2 squamous cell carcinomas of the skin
29.History of clinically significant (as determined by [CONTACT_093]) non -PAH related
cardiac, endocrine, hematologic, hepatic, immune, metabolic, urologic, pulmonary,
neuro logic, neuromuscular, dermatologic, psychiatric, renal, and/or other disease that
may limit participation in the study
30.Participation in another clinical trial involving intervention with another investigational
drug, approved therapy for investigational us e, or investigational device within [ADDRESS_184728] is known, within 5Ã— the half -life
prior to C1D1, whichever is longer
31.Unwillingness or inability to comply with the protocol -required procedures
5.3. Screen Fa ilures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not eligible to receive study treatment.  Electronic case report forms need to be completed for all 
patients who sign the informed consent.  A minim al set of screen failure information is required 
to ensure transparent reporting of screen failure participants to meet the Consolidated Standards 
of Reporting Trials (CONSORT) publishing requirements and to respond to queries from 
regulatory authorities.  Minimal information includes demography, reason for screen failure 
adverse events, eligibility criteria.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened once with the approval of the study medica l monitor.  Rescreened participants will be 
assigned a new participant number.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184729] consi
sts of sotatercept in 10 mM citrate buffer, pH 5.8, 8% sucrose, 
and 0.02% polysorbate 80.  It is supplied as a
 lyophilized powder in labeled, rubber stopper
ed, 
3-mL glass vials.  The recommende
d storage temperature for sotatercept lyophilized drug 
product is 2Â°C to 8Â°C.  Prior
 to administration, the lyophilized drug product is reconstituted with 
[ADDRESS_184730] consists of a 50 mg/mL soluti
on of 
sotatercept.  The reconstituted sota
tercept, in its original container closure system, may be held 
for up to 6 hours at 2Â°C to 8Â°C.  For details, refer to the Pharmacy Ma
nual provided under a 
separate cover.  
SOC treatments will be prov
ided by [CONTACT_159105] 
(see Appendix  3 for more details on SOC).  
6.2. Treatment Administrat
ion and Schedule  
Subcutaneous (SC) s otatercept will be administere
d after reconstitution as an SC injection to 
participants by [CONTACT_159106].  Subcutaneous injections will be given in t
he upper arm, abdomen, or thigh.  
Where rounding the weight and total volum
e is necessary, please refer to the Pharmacy Manual 
for further details.  
Sotatercept dosing is weight based ther
efore an overdose would only be considered if the dose 
exceeds the no -observed -adverse -effect level (NO
AEL) of 1 mg/kg.  For information on 
overdose, refer to Section  8.3.[ADDRESS_184731] remain on the same SOC trea
tments during the  study (see 
Section  4.3 and Appendix  3 for more details on SOC).  
6.3. Dose Modifica
tion 
Dose delay and/or reduction or
 discontinuation may be required for sotatercept. Guidance for 
dose modifications and dose delay a
re summarized in Figure  2 and Figure  3.  The details of Dose 
Modification Guidance are
 based on the results of platelet and Hgb values duri ng the Treatment 
and Extension Periods.  Dose delays and reduc
tions can be implemented for safety reasons at any 
time per Investigatorâ€™s assessme
nt, not being restricted to the Dose Modification Guidance 
provided.  
A maximum of 3 dose delays are allowed bas ed on safety monitoring during the study
.  
If a fourth dose delay is required, the study tre
atment should be discontinued .  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184732] be directed to the medical monitor.   
Results from the hematology panel should be evaluated prior to study drug administration.  For 
C1D1 and C2D22 visits, blood samples should be taken and assessed for Hgb levels on the same 
day as study drug administration or 1 day prior.  If Hgb increases are > 4.0 g/dL above the 
participant baseline value, the medical monitor should be consulted, and study drug 
discontinu ation should be considered.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184733] 2021 
Acceler on Pharma Inc.  Page 35 of 93 CONFIDENTIAL  Figure  2: Platelet Count Dose Modification: Dose Delay, Dose Reduction and Discontinuation Guidelines  
 
PLT = platelet.  
 
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184734] 2021 
Acceleron Pharma Inc.  Page 36 of 93 CONFIDENTIAL  Figure  3: Hemoglobin Dose Modification: Dose Delay, Dose Reduction and Discontinuation Guidelines  
Hgb = hemoglobin  
Once Hgb returns to the required value for dose administration, the re -starting dose will be administered at the next planned cycle or if it is the first cycle, after a 
3-week dose delay.
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184735]  2021 
Acceleron Pharma Inc.  Page 37 of 93 CONFIDENTIAL  Leukopenia and neutropenia are define
d as AESI  in Section  8.4. 
A dose reduction of study drug will be maintaine
d unless subsequent dose reductions are 
indicated.  No more than 2 dose reductions a
re allowed.  If dose reductions were done due to an 
AE not  related to study drug, the dose can be es
calated when the AE is resolved.  In cases of 
dose reduction due to increases in Hgb, t
he dose can be re -escalated after 2 consec
utive cycles in 
which Hgb values are stable and equal or lowe
r than the upper limit o f normal.  
Table  6: Dose Reductions for Sotate
rcept  
Starting Dose Level First  Dose Level 
Reduction  Second  Dose Level 
Reduction  
0.3 mg/kg 0.1 mg/kg 0.05 mg/kgNo additional dose 
reductions permitted;
 
discontinue treatmen
t 
0.7 mg/kg 0.3 mg/kg 0.1 mg/kg
6.4. Method of Treatment Assig
nment  
This is a non -randomized, open -label, single treatment study.  Participants who meet all 
inclusion and none of the exclusion criteria 
will receive all study treatments according to the 
Schedule of Events ( Table  3). 
6.5. Randomization a
nd Blinding  
This is an open -label, non -randomized study.  
6.6. Packaging and La
belin g 
The study drug will be labeled per local re
quirements . 
6.7. Preparation/H
andling/Storage/Accountability  
Accountability for study drug that is administ
ered during the course of the study is the 
responsibility of the investigator or designee.  
Investigational c linical supplies must be receiv
ed 
by a designated person at the clinical site a
nd kept in a secure and temperature -controlled 
location.  The investigational site must maintain ac
curate records demonstrating dates and 
amounts of study drug received, to whom  it was administered (participant -by-participant 
accounting), and accounts of a
ny sotatercept accidentally or deliberately destroyed or returned.  
Accurate recording of all
 study drug administration is to be made in the appropriate section of 
the participa ntâ€™s electronic case re
port form (eCRF) and source documents.  Unless otherwise 
notified, all vials of study drug, both used and unused, must be save
d for drug accountability.  
The used vials may be discarded, pe
r the institutionâ€™s standard practice, after  drug accountability 
has been completed by [CONTACT_2037].  The
 investigator must return all unused vials of study drug 
to the sponsor at the end of the study, or the study
 drug may be destroyed at the clinical site with 
permission of the sponsor.  For either  scenario, the outcome must be documente
d on the drug 
accountability log.  The sponsor or designee 
will provide direction for the outcome of all unused 
vials.  
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184736]  2021 
Acceleron Pharma Inc.  Page 38 of 93 CONFIDENTIAL  Acceleron (or designee) will
 review with the investigator and relevant site personnel the process  
for IP return, disposal, and/or de
struction including responsibilities for the site versus Acceleron 
(or designee).  
Refer to the Pharmacy Ma
nual for further instructions for preparation of study treatments and 
information regarding disposition of unused s tudy treatments.  
6.8. Treatment Compliance  
Each dose of study treatment will be admi
nistered by [CONTACT_10530](s) at the clinical site by [CONTACT_159107]
e record.  Accurate recording of all study 
drug administration will  be made in the appropriate sec
tion of the participantâ€™s eCRF and source 
documents.  The investigator or designee is responsibl
e for accounting for all study drug that is 
administered during the course of the
 study.  
Standard of care treatme
nt compliance wi ll be the responsibility of each pa
rticipant and his/her 
treating physician.  The investigator should promote compliance by [CONTACT_159108]
d and by [CONTACT_159109]â€™ s safety and the validity of the study.  The pa
rticipant should be instructed to contact 
[CONTACT_087]/she is unable for any rea
son to take their SOC medication as prescribed 
(see Appendix  3 for more details regarding SOC).  
SOC in the Extension Period is per the Investigatorâ€™s discretion ( see Section  6.9). 
6.9. Concomitant Therapy  
During screening and throughout the Treatm
ent Period of the study, participants may take stable 
doses of medications for chronic conditions t
hat are not specifically exc luded by [CONTACT_760].  If 
there is an immediate clinical need during the
 study to prescribe a new medication or a new 
dosage of an existing medication fo
r either a new or chronic condition, concurrent therapy may 
be administered at the disc
retion of the i nvestigator.  If the new medicati
on is a PAH -specific 
medication that is being added for clinica
l worsening (i.e., rescue therapy, refer to Section 8.5.5  
for sugge sted criteria), or is disallowed by [CONTACT_159110] c
riteria (e.g., systemic corticosteroid), the 
investigator will need to discontinue study drug
 treatment and perform EOT visit assessments as 
directed by [CONTACT_760].  The investigator may c
onsult the medical moni tor regarding what 
constitutes a stable dose or a chronic
 condition.  Information regarding concomitant medications 
will be collected after signing of the 
ICF and will include all medications taken during the 
Screening Period to C1D1.  
During the Extension Period, partic
ipants under investigatorâ€™s supervision can substit
ute, 
remove, or adjust the dose of SOC for PAH -worsening and chronic concomitant m
edications, 
including supplemental oxygen.  Investigator discreti
on will be used to dete rmine if sotatercept 
study drug discontinuation is necessary.  
If patients need additional concomi
tant medications , it should be recorded in the appropriat
e 
eCRF.  Study drug can be adjust
ed or discontinued due to concomitant therapy based on the 
Investigat orâ€™s discretion.  The investigator may consult the medica
l monitor regarding 
discontinuation or modification of study tre
atment on a case -by-case basis.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184737]  2021 
Acceleron Pharma Inc.  Page 39 of 93 CONFIDENTIAL  7. DISCONTINUA
TION/WITHDRAWAL CRITERIA  
The reason for treatment disconti
nuation/study withdrawal must be  recorded in the 
corresponding participantâ€™s eCR
F.  The investigator must notify the sponsor and medical 
monitor when a participant has discontinued trea
tment or been withdrawn from the study.  All 
participants who are discontinued/withdrawn f
rom the study  prior to the EOT visit should 
complete the tests and evaluations scheduled f
or the EOT visit at the time of 
discontinuation/withdrawal and will be asked to r
eturn to the clinic to complete the remaining 
Follow -Up EOS visit.  
7.1. Discontinuatio
n of Study Treatm ent 
Reasons that may lead to discontinua
tion of study treatment include the following:  
â€¢ Completion of treatment  
â€¢ AE or serious adverse event (S
AE) 
â€¢ Participant request (withdrawal of c
onsent)  
â€¢ Clinical worsening requiring rescue the
rapy with a PAH agent  
â€¢ Pregnancy  
â€¢ Protocol deviation  
â€¢ Study terminated by [CONTACT_3211]  
â€¢ QTcF > 500  ms during treatment period  
Clinical worsening, pregnancy, and Q
TcF > 500 ms should be recorded as an AE, see 
Section  8.3.  
The sponsor may terminate study treatment or a
 dose level after consultation with the 
investigator at any time for safety or admi
nistrative reasons.  The sponsor will terminate the 
study if the occurrence of SAE
s or other findings suggests unacceptable risk to t
he health of the 
participants.  Refer to Section  6.3, Dose Modification , for further information reg arding AEs that 
can lead to discontinuation.  
7.2. Withdrawal from the Study  
Reasons that may lead to a pa
rticipantâ€™s withdrawal from the study include:  
â€¢ Participantâ€™s request (withdrawal of c
onsent)  
â€¢ Screen failure  
â€¢ Participantâ€™s unwillingness or inability to comp ly with the protocol  
â€¢ AE with an outcome of death  
â€¢ Death  
â€¢ Lost to follow -up 
â€¢ Study termination by [CONTACT_456]  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184738]  2021 
Acceleron Pharma Inc.  Page 40 of 93 CONFIDENTIAL  â€¢ AE or SAE  
â€¢ Pregnancy  
Serious Adverse Events and AEs, including those with an outc
ome of death or pregnancy, should 
be recorded as an (S)AE (see Section  8.3).   
If the participant withdraws from the study and a
lso withdraws consent for disclosure of future 
information, no further evaluations should be performed,  and no additional data should be 
collected.  The sponsor may retain a
nd continue to use any data collected before such withdrawal 
of consent.  
If a participant discontinues due to an A
E or other medical reason, the participant must continue 
to be followed at regular inte
rvals until the AE no rmalizes or returns to the participantâ€™s bas
eline 
condition, as per Section  8.3.5 . 
Participants to whom rescue ther
apy is administered (see  Section  8.5.5 ) after demonstrating 
clinical worsening criteria ( Section  8.5.4 ) must discontinue study drug and must
 be withdrawn 
from the study.  
7.3. Lost to Follow -Up 
A participant  will be considered lost to follow -up if he or she repeatedly fails t
o return for 
scheduled visits and is unable to be contact[CONTACT_159111].  
The following actions must be taken if a pa
rticipant fails to return to the clinic for a required 
study visi t: 
â€¢ The site must attempt to contac
t the participant and reschedule the missed visit as 
soon as possible and counsel the
 participant on the importance of maintaining the 
assigned visit schedule and ascert
ain whether or not the participant wishes to and/or 
should continue in the study.  
â€¢ Before a participant is de
emed lost to follow -up, the investigator or designee must 
make every effort to rega
in contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a
 certified letter to the partic ipantâ€™s last known mailing 
address or local equivalent methods).  T
hese contact [CONTACT_14316]â€™s study source r
ecord.  
â€¢ Should the participant continue to be unr
eachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up, which should be 
noted on the participantâ€™s eCRF.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184739]  2021 
Acceleron Pharma Inc.  Page 41 of 93 CONFIDENTIAL  8. STUDY ASSESSMENTS AND
 PROCEDURES  
â€¢ Study procedures and their timing a
re summarized in the Schedule of Events (SoE) 
(Section  2). 
â€¢ No protocol waivers or exemptions will be
 allowed for eligibility criteria. 
Assessments performed outside
 of their defined windows will be handled as protocol 
deviations.  
â€¢ Immediat e safety concerns should be discusse
d with the sponsor immediately upon 
occurrence or awar
eness to determine if the participant should continue or 
discontinue study treatment.  
â€¢ Adherence to the study de
sign requirements, including those specified in the SoE  
(Section  2), is essential and required for study conduc
t. 
â€¢ All screening evaluations must be completed a
nd reviewed to confirm that potential 
partici pants meet all eligibility criteria
.  The investigator will maintain a screening log 
to record details of all participants scr
eened and to confirm eligibility or record 
reasons for screening failure
, as applicable.  
â€¢ Procedures conducted as 
part of the participantâ€™s routine clinical ma
nagement 
(e.g.,  blood count) and obtained before signing of the IC
F may be utilized for 
screening or baseline purpose
s provided the procedures met the protocol -specified 
criteria and were perf
ormed within the timeframe defined i n the SoE ( Section  2). 
â€¢ All protocol assessments are to be reco
rded on the participantâ€™s source 
documentation.  
â€¢ EOS Assessment visit is the point at which the post [ADDRESS_184740]-18-month Extension Period outcome measures are
 assessed.   
8.1. Screening Procedures  
â€¢ Screening procedures a
re to be performed as per the SoE ( Section  2) and are to be 
completed and reviewed by [CONTACT_159112].  
â€¢ Procedures also include re
view of participantâ€™s medical, surgical, and family histor y; 
collection of demographics, r
ace, and ethnicity; and requests for medical records for 
external procedures.  
8.2. Efficacy Assessm
ents 
8.2.1.  iCPET  
Invasive CPET (iCPET) will be
 performed at the Screening, Cycle 9, and Cycle [ADDRESS_184741] after other ass
essments.  
At the end of the 24 -week Treatment Period (
Cycle 9, Day 169), Cycle 17 of the 18 -month 
Extension Period, the cardiac MR im
aging and iCPET may be done on separate days.  If 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184742]  2021 
Acceleron Pharma Inc.  Page 42 of 93 CONFIDENTIAL  performed on the same day, iCP
ET shoul d be performed before cardia
c MR, with â‰¥ 1 hr interval 
between procedures.  
RHC will be performed as per the iCP
ET manual.  Zero -pressure calibratio
n will be performed at 
the mid -axillary line with the patie
nt in a supi[INVESTIGATOR_2547].  Superior vena cava (SVC) , right atrial 
(RA), right ventricular (RV), PCW, and PA pressures will
 be measured, and mean vascular 
pressures will be calculate
d based on systolic and diastolic pressure measurements.  Heart rate 
and vascular pressures ar
e monitored continuously.  Cardi ac output is measured by [CONTACT_941] F
ick 
method.  Diastolic and transpulmonary pressure
 gradients are obtained, systemic and PVRs are 
calculated.  
8.2.2.  Cardiac Magnetic Reson
ance Imaging  
Cardiac MR imaging will be perf
ormed at Screening and at multiple time points throughout the 
study as per the SoE ( Section  2).  Cardiac MR imaging m ust include the first bullet below.  
Assessment of cardiac structure
 and function (SSFP sequences).  The subsequent analyses are to 
be collected, if possible:  
â€¢ Assessment of cardiac structure
 and function (SSFP sequences);  
â€¢ Hemodynamic assessment of valvular  flow (phase -contrast imaging), including 
pulmonary -systemic flow ratio (Qp/Qs);  
â€¢ Assessment of diffuse fibrosis (using T1 mappi[INVESTIGATOR_007]);  
â€¢ Pulmonary artery (PA) compl
iance and vessel wall remodeling (using high -temporal 
resolution sequences).  
Specific cardiac MR imaging measurements releva
nt to the PAH pathophysiology include the 
following: structural anatomy and morphology of cardiac
 chambers; functional performance of 
the RV and the LV; anatomy and morphology of grea
t vessels; anatomic and hemodynamic 
findings s uggestive of an intra -cardiac shunt; presence
 of scar/fibrosis of the LV and/or RV.   
In addition to the views collec
ted according to established methods and protocols, the following 
views and series are of vital int
erest and must be collected, if possible , for evaluation:  
a. 3-plane loc  
b. Transaxial black blood from above arc
h to diaphragm  
c. 2-chamber cine localizer  
d. Short -axis cine localizer  
e. 4-chamber cine stack and locali
zer 
f. 2-chamber cine  
g. Short -axis cine  
h. Short -axis T1 map of base and mid ve
ntricle  
i. Rvot cine  
j. Oblique cines of the RT, LT, and main pulmonary a
rt 
k. Velocity encoding (vencs) of the pulmonary arte
ry, ascending aorta, and the mitral 
and tricuspid valves  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184743]  2021 
Acceleron Pharma Inc.  Page 43 of 93 CONFIDENTIAL  Further details of the cardiac
 MR imaging can be found in the imaging protocol.  
Cardiac MR images will be
 centrally read and details of central read can be found in the imaging 
review charter.  Cardiac 
MR and iCPET should be done on separate days.  If performed on the 
same day, iCPET should be performed befor
e cardiac MR, with â‰¥ [ADDRESS_184744] after other a
ssessments (i.e., 6-meter  walking test [ 6MWT ]) have been 
completed.  
The first RHC must be performed with in 10 days prior to C ycle 1 (during the Screening Period)
, 
the second RHC should be performed withi
n 10 days prior to the 24 -week Treatment 
Period/C ycle 9 visit (during the Treatment Period) , and the third RHC should be performed 
within 10 days of C ycle 17 (during the Extension Period).  R
HC should be performed Â±10 days 
of the EOT visit or at the time of their disconti
nuation for participants who discontinue prior to 
24 weeks/C ycle 9.  RHC will assess the long -term benefits and durability of the e
ffect of 
sotatercept treatment.   
A participant will not receive more than 3 RHC asse
ssments during the study.  
Right heart catheterizati
on will be performed according to the iCPET manual and is to assess 
several prognostic hemodynami
c variables in addition to PVR, including right atrial pressure 
(RAP), mean PAP, mean PCW
P, and cardiac output (CO).  The following hemodynamic 
parameters will be assessed when the p
articipant is in a stable hemodynamic rest state (as 
demonstrated by 3  consecutive mean PAP and CO measure ments within 10% of each other) 
while the participant is breathing ambi
ent air or oxygen:  
â€¢ RAP, mean PAP, mean PC
WP, systolic pulmonary artery pressure, diastolic 
pulmonary artery pressure, systoli
c BP, diastolic BP, heart rate (HR)  
â€¢ CO measured in triplicat e by [CONTACT_159113]
e will be calculated and populated in the eCRF.  Right ventricle 
pressure data from the RHC with simultane
ously recorded ECG recordings may be collected and 
digitally stored at selected sites.  
8.2.4.  Six-Minute Walk Distance  
Six minute walk distance will be
 measured by [CONTACT_941] 6MWT at Screening and at multiple time 
points throughout the study as per Section  [ADDRESS_184745] be within 
15% of each other, based on the longe
r distance.  If the difference between the first and second 
tests is > 15%, the test may be repea
ted once more, provided the repeat test is within [ADDRESS_184746].  If the differe
nce between the distances remains >  15%, the participant will be 
considered a scree
n failure.  If occurring on the same day, 6M WT should be performed before
 
RHC.  Appendix  4 provides further instructions on 6MWT.  For 
assessment of clinical 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184747]  2021 
Acceleron Pharma Inc.  Page 44 of 93 CONFIDENTIAL  worsening, a decrease of â‰¥  15% in 6MWD at any time point as compared to Screening must be 
confirmed by a second 6MWT performed at least [ADDRESS_184748].  
8.3. Adverse Events  
8.3.1.  Adverse Event Definitions  
[IP_ADDRESS].  Adverse Event s 
An AE is any untoward medical occurrence in a clinical investigation participant administered a 
study drug, which does not necessarily have a causal relationship with this treatment.  An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or d isease temporally associated with the use of the study drug  whether or not it is 
considered related to study drug.  
Abnormal laboratory and other abnormal investigational findings (e.g., physical examination, 
ECG) should not be reported as AEs unless they a re associated with clinical signs and symptoms, 
lead to treatment discontinuation, or are otherwise considered clinically relevant by [CONTACT_1275].  In cases of surgical or diagnostic procedures, the condition/illness leading to such a 
procedure is con sidered as the AE rather than the procedure itself.  In case of a fatality, the cause 
of death is considered as the AE, and the death is considered as its outcome.  
[IP_ADDRESS].  Unexpected Adverse Events  
An unexpected AE is an AE that, the nature, severity, specificity,  or outcome of which is not 
consistent with the summary of product characteristics described in the IB under the Reference 
Safety Information.  
[IP_ADDRESS].  Events Not to Be Considered as Adverse Events  
Pre-existing medical conditions/signs/symptoms present 30 days prio r to the Screening Period 
that do not worsen in severity or frequency during the study are defined as Baseline Medical 
Conditions and are not to be considered AEs.  Anticipated day -to-day fluctuations of pre -existing 
conditions, including the disease under  study, that do not represent a clinically significant 
exacerbation or worsening need not be considered AEs.  
[IP_ADDRESS].  Serious Adverse Event  
An SAE is any AE, occurring at any dose level/regimen and regardless of causality that:  
â€¢ Death: An adverse event that results in death e.g., cardiac arrest . 
â€¢ Life threatening: Is an AE in which the patient was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it 
were more severe . 
â€¢ Requires inpatient hospi[INVESTIGATOR_159070]; 
however, a hospi[INVESTIGATOR_159071].  
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184749]  2021 
Acceleron Pharma Inc.  Page 45 of 93 CONFIDENTIAL  â€¢Results in persistent or significant di
sability/incapacity.  An AE is incapacitating or
disabling if the experience results  in a substantial and/or permanent disruption of the
subject's ability to carry out normal life
 functions.
â€¢Is a congenital anomaly/birth de
fect: Congenital anomaly/birth defect in a child of a
subject or its partner that was expose
d to study drug prior to conception or during
pregnancy.
â€¢Other, is an important medical event: An important medic
al event is an event that
may not result in death, be life -threatening, or require hospi[INVESTIGATOR_313] m
ay be
considered an SAE when, ba
sed upon appropriate medical jud gment, it may
jeopardize the patient and may re
quire medical or surgical intervention to prevent one
of the outcomes listed in the definitions for SAEs.  Exa
mples of such medical events
include allergic bronchospasm requiring i
ntensive treatment in an emer gency room or
at home, blood dyscrasias, or convulsions that do not
 result in inpatient
hospi[INVESTIGATOR_059], or the development of drug dep
endency or drug abuse.
For the purposes of reporting per r
egulations, any suspected transmission of an infectious agent 
via a medical product is by [CONTACT_15094] a suspe
cted unexpected serious adverse reaction (S[LOCATION_003]R) 
and should be reported in an expedited mann
er as described in Section 8.3.7 . 
[IP_ADDRESS].  Events Not to Be Consider
ed as Serious Adverse Events are Hospi[INVESTIGATOR_5315]:  
â€¢A standard procedure for protocol t
herapy administration.  However, hospi[INVESTIGATOR_159072] a compl
ication of therapy administration will be
report ed as an SAE.
â€¢Routine treatment or monitoring of the studie
d indication not associated with any
deterioration in condition.
â€¢A procedure for protocol/disea
se-related investigations (e.g., surgery, scans
,
endoscopy, sampling for laboratory tests, bone marrow  sampling).  However,
hospi[INVESTIGATOR_27589] a 
complication of such procedures
remains a reportable SAE.
â€¢Hospi[INVESTIGATOR_159073], practical, or social
reasons, in absence of an 
AE.
â€¢A proced ure that is planned (i.e., planned prior to star
ting of treatment on study);
must be documented in the source document a
nd the eCRF.  Hospi[INVESTIGATOR_159074] a complicati
on remains a reportable SAE.
â€¢An elective treatment of a
 pre-existing condition unrelated to the studied indica
tion.
â€¢Emergency outpatient treatm
ent or observation that does not result in admission,
unless fulfilling other seriousness crite
ria above.
If an AE is considered serious, both the AE
 page/screen of the eCRF and the SAE R
eport Form 
must be completed.  
For each SAE, the investigator will prov
ide information on severity, start and stop dates, 
relationship to IP, rationale of the c
ausality, the action taken regarding IP, and outcome.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184750]  2021 
Acceleron Pharma Inc.  Page 46 of 93 CONFIDENTIAL  [IP_ADDRESS].  Severity  
Investigators mu st evaluate the severity/intensity of AEs and SAEs according to the current 
active version of the NCI -CTCAE (NCI -CTCAE) , preferentially using the graded scales.  If 
there is a change in severity of an AE, it must be recorded as a separate event.  If a part icular 
AEâ€™s severity/intensity is not specifically graded, the investigator should apply the general 
guidelines for determination of Grade 1 through Grade 5 as listed in the NCI -CTCAE cover page 
(as shown below), using their best medical judgment:  
Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2:  Moderate; minimal, local, or noninvasive intervention indicated; limiting age 
appropriate - instrumental activities of daily living (prepari ng meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.).  
Grade 3:  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self -care 
activities of daily living (bathing, dressing and undressing, feeding self, using the toilet, 
taking medications, and not bedridden).  
Grade 4:  Life-threatening consequences; urgent intervention indicated.  
Grade 5:  Death related to AE.  
The term â€œsevereâ€  is often used to describe the intensity of a specific event (as in mild, moderate, 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as â€œ serious,â€ which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subjectâ€™s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.  
8.3.2.  Relationship to Study Drug  
The investigator must determine the relationship between the administration of study drug and 
the occurrence of an AE/SAE as Not Suspected or Suspected as defined below.  Factors for the 
assessment of causal relationship include, but are not limited to, te mporal relationship between 
the AE and the administration of study drug, known side effects of study drug, concomitant 
therapy, course of the underlying disease and pertinent study procedures.  
Not Suspected:  Means a causal relationship of the AE to study d rug administration is 
unlikely or remote, or other medications, therapeutic interventions, or underlying conditions 
provide a sufficient explanation for the observed event.  
Suspected:  Means there is a reasonable possibility that the administration of study  drug 
caused the AE.  â€œReasonable possibilityâ€ means there is evidence to suggest a causal 
relationship between the study drug and the AE.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184751] ing AEs and/or SAEs.  Open -ended and non -leading verbal questioning of the participant is 
the preferred method to inquire about AE  occurrences.  All clearly re
lated signs  and symptoms 
which are either volunteered by [CONTACT_159114] f ollowing the course of 
investigational product administration mus
t be reported on the appropriate eCRF.  AEs and SAEs 
reported from the signing of the ICF to the EOS
 visit are to be reported and documented on the 
AE eCRF.  Any AE related to a pr
otocol proc edure should be marked as suc
h on the eCRF.  
All AEs spontaneously reported by [CONTACT_4538]/or
 in response to an open question from 
study personnel or revealed by [CONTACT_159115], physical examination, or other diagnostic procedures 
will be recorded on the AE eCRF.  Any clinically re
levant changes in laboratory assessments or 
other clinical findings as described in Section  [IP_ADDRESS]   are considered AEs and mus
t be recorded 
on the AE eCRF.  AEs are to be f
ollowed for resolution as described in Section  8.3.5 . 
It is important that each AE re
port include a description of the eve
nt, duration (onset and 
resolution dates), severity, relationship with sotater
cept, any other potential causal factors, any 
treatment given or other ac
tion taken (including dose modification or discontinuation of 
sotatercept ), and outcome.  In addition, SAEs shoul
d be identified and the appropriate 
seriousness criteria documented.  AEs c
ategorized as SAEs must also be documented within the 
appropriate SAE section in the e
CRF or a paper SAE form if the system is down or otherw ise 
unavailable , as described in Section  8.3.[ADDRESS_184752] 1 dose of study drug, 
whether they completed the Trea
tment Period or not, should complete the EOT and EOS visits.  
All AEs will be followed until return to screening baseline
, resolution, or clinical database lock.  
All SAEs will undergo active follow -up until resolved or the event becomes c
hronic or stable.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184753] 
research organization (CRO)
 by [CONTACT_756], fax, or email.  Per Section  8.3.[ADDRESS_184754] 
be completed by [CONTACT_159116].  Names, addresses, 
email addresses, and telephone and fax number
s for SAE reporting are located on the SAE 
Report Form and in the completion, instructions provided for the Investigat
or Site File.  When an 
SAE (or follow -up information) is reported by [CONTACT_756], a written report 
must be sent 
immediately thereafter by [CONTACT_159117].  Reporti ng procedures and timelines for follow -up 
information are the same as for the initially reporte
d SAE.  
Relevant pages from the eCRF may be
 provided in parallel (e.g., medical history, concomitant 
therapy).  In all case
s, the information provided in the SAE Report Form must be consistent wit
h 
the data that are recorded in the
 corresponding sections of the eCRF.  
The investigator/reporter must respond to a
ny request for follow -up information or to any 
question the sponsor or designee may have on the AE
 with in the same timelines as describ
ed for 
initial reports.  This is necessary to permit a pr
ompt assessment of the event by [CONTACT_23638] 
(as applicable) to allow the
 sponsor to meet regulatory timelines associated with expedited 
reporting obligations.  
Requ ests for follow -up will usually be made by [CONTACT_159118]
l research associate or 
medical monitor, or an Accele
ron pharmacovigilance representative who may contact [CONTACT_159119] a particularly critical event.  
8.3.7.  Safety Reporting to Health Author
ities, Independent Ethics Committees, 
Institutional Review Boards, and Inve
stigators  
The sponsor will send appropriate safety notific
ations to Health Authorities in accordance with 
applicable laws and regulati
ons. 
The inves tigator must comply with any applicable
 site-specific requirements related to t
he 
reporting of SAEs involving his/her participants to the IEC that appr
oved the study.  
In accordance with 
International Council for Harmonisation (ICH) Good Clinical Practice ( GCP) 
guidelines, the sponsor will inform the investigator of â€œ
findings that could adversely affect the 
safety of participants, impact the conduc
t of the study, or alter the IECâ€™s approval/favorable 
opi[INVESTIGATOR_43932].â€  
The sponsor will inform th e investigator of AEs that are both se
rious and unexpected and are 
considered to be related to sotater
cept (S[LOCATION_003]Rs).  The investigator should place copi[INVESTIGATOR_159075].  National regulations with regard to Safety Re port 
notifications to investigators will be followed.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184755] information.  
Sotaterc ept dosing is weight -based therefore, for purpose of this t
rial, an overdose is defined as 
any dose that has exposures in excess of monkey NOAEL dose of 1 mg/kg ( IB Edition 14 , 
Section 3.3.2, Table 4 ), which was also the highest dose tested in hum
an volunt eers study 
(Study  A011 -02) with resolvable AEs.  Any instance of ov
erdose (suspected or confirmed and 
irrespective of wheth
er or not it involved sotatercept) as defined in the protocol, with or without 
an AE, must be communicated to Accele
ron or a specifie d designee within 24 hours and be fully 
documented as an AE in the eCR
F.  
There is no antidote for sotaterc
ept, and it is not dialyzable from blood, therefore in case of 
overdose patients should be monitore
d/treated as per clinical practice based on sympto ms of 
identified and potential risks as described in the I
B. 
8.3.9.  Transmission of an Infec
tious Agent  
Definition: Transmission of an infecti
ous agent via study drug administration.  Any organism, 
virus, or infectious particle (e.g., protein tr
ansmitting transmi ssible spongiform encephalopathy), 
pathogenic or non -pathogenic, is considered a
n infectious agent.   
Transmission of an infectious age
nt may be suspected from clinical signs or symptoms or 
laboratory findings indicating an infe
ction in a patient exposed t o study drug.  As in the case of 
suspected adverse reacti
ons and adverse reactions, the terms suspected transmission and 
transmission are considere
d synonymous.  
In the context of evaluating a suspec
ted transmission of an infectious agent via study drug 
administration, care should be taken to di
scriminate, whenever possible, between the cause 
(e.g.,  injection/administration) and the sourc
e (e.g., contamination) of the infection and the 
clinical conditions of the patient at the time
 of the infection (immune -suppressed/vaccine).  
Any instance of transmission of a
n infectious agent must be communicated to Acceleron or a 
specified designee within 24  hours to the sponsor using appropriate channels (e
.g., telephone, 
email)  and be fully documented as an AE in the
 eCR F, or as an SAE if associated S
AE occurs 
(see Section  8.3 for further instruction).  
8.3.10.  Pregnancy  
The investigator will attempt to collect pregna
ncy information if a female participant or a male 
participantâ€™s female partner bec
omes pregnant while the participant is participating in this study 
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184756] be submitted to the sponsor within 24 hours of 
learning of the pregnancy.  The participant or
 partner will be followed for the outcome of the 
pregnancy.  Information on the sta tus of the mother and child will be forwarded to t
he sponsor or 
designee.  Generally, follow -up will be no longer than 6 to 8  weeks following the estimated 
delivery date.  Any premature ter
mination of the pregnancy will be reported as an AE.  
Abnormal preg nancy outcomes (e.g., spontane
ous abortion [includes miscarriage and missed 
abortion], fetal death, stillbirth, conge
nital anomalies, ectopic pregnancy, neonatal death) are 
considered SAEs.  Any neonatal dea
th that occurs within [ADDRESS_184757] dose.  
â€¢If a pregnancy is rep orted, the investigator must inform the sponsor within 24 hours
of learning of the pregnancy and should follow the pr
ocedures outlined in
Appendix  8.
â€¢Additional pregnancy, breastfee
ding, and sperm/ovum donor information is provided
in Appendix  8.
8.4. Monitoring of I
dentified, Potential and Adverse Events of Special 
Interest  
The risks outlined below are consistent wit
h the list in Sotatercept IB ( IB Edition 14 ).  The AESI 
are considered important pa
rameters to be monitored in order to assess the overall safety of the 
PAH patient population, therefor
e, added  for safety monitoring in the sotaterc
ept clinical trial.  
The lab oratory  data and vital signs are monitore
d on an ongoing basis by [CONTACT_159120].  Laboratory data and AE
s are measured as per the study schedule 
or upon an unscheduled visit if appli
cable.  Section  6.[ADDRESS_184758] safety signal detection and  
medical monitoring.  
8.4.1.  Identified Risk  
Table  7 describes the identified risks that could occur du
ring the study drug treatment.  
Table  7: Identified Risks  
Description  Monitor Parameter  Planned Action  
Blood pressure 
increase  Hypertension SMQ 
(Narrow and broad)  Monitor the vital s
igns for any hypertension 
trending in combin
ation with the events reported.  
Additionally, review for
 risk factors of systemic 
hypertension (diabete
s, metabolic syndrom e, and 
obesity), concomitan
t medications, and previous 
medical history of
 hypertension.  
SMQ = standardized Med
DRA queries  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184759]  2021 
Acceleron Pharma Inc.  Page 51 of 93 CONFIDENTIAL  8.4.2.  Potential Risks  
Laboratory  data and AEs are measured 
as per protocol schedule or upon an unscheduled visit if 
applicable.  Section  6.3 provides details for dose modificati
ons due to decreases in hematocrit 
and/or platelet s.  Table  8 provides potential risks that could occur during study drug tre
atment.  
Table  8: Potential Risks  
Description  Monitor Parameter  Planned Action  
Increase in RBC   RBC parameters  
(RBC, Hgb, and Hct)  â€¢ Careful monito
ring of RBC parameters is 
performed and in case o
f Hct â‰¤ 55%  
â€¢ Dose hold and/or dose de
crease guidance 
is to be followed  
Additionally  
â€¢ Monitor by [CONTACT_159121] (Hgb/Hct)  
â€¢ The medical monitor
 will ensure dosage 
adjustment according 
to the protocol  
â€¢ Monthly review of Hct /Hgb listings by 
[CONTACT_159122] m
ember (hematology expert)  
Immunogenicity f
or 
biologic  
Compound  Anaphylactic reacti
on 
(SMQ) (Narrow an
d 
broad) and 
Hypersensitivity 
(SMQ) 
(Narrow and broad)  â€¢ Immunogenicity wi
ll continue to be 
evaluated on reported e
vents  
â€¢ The study sampling of ant
i-drug antibody 
is to be reviewed at t
he end of the study  
Renal toxicity  Acute renal fail
ure 
(SMQ) (Narrow an
d 
broad)  â€¢ Renal  monitoring of A
Es in a combination 
of lab oratory  data monitoring of
 UA of 
protein/blood and eGFR  
AE = adverse event; eGFR  = estimated glomerular
 filtration rate; Hct  = hematocrit; Hgb  = hemoglobin; RBC  = red 
blood cell; SMQ  = standardized Med
DRA queries; UA  = urinalysis  
8.4.3.  Adverse Events of Spec
ial Interest  
Table  9 describes AESIs  that may occur during study drug treatment.  
Table  9: Adverse Events of Spec
ial Interest  
Description  Monitor Parameter  Planned Action  
Fertility disorders 
with a focus on 
suppression of FSH  SMQ fertility di
sorders  Fertility disorders wi
th a focus on FSH monitoring 
of AEs and lab oratory  data review of FSH   
Hepatic toxicity  Hepatic disorder
s 
(SMQ) (Narrow an
d 
broad)  Hepatic monito
ring of AEs in combination of 
laboratory  data Hyâ€™s law lab oratory  data 
monitoring AST
, ALT, ALP  
Cardiac events and 
Embolic and 
thrombotic event
s  Ischaemic heart 
disease 
(SMQ)  Monitor of AEs in com
bination of risk factors of 
systemic hypertensi
on (diabetes, metabolic 
syndrome, obesity), conc
omitant medications, 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184760]  2021 
Acceleron Pharma Inc.  Page 52 of 93 CONFIDENTIAL  Description  Monitor Parameter  Planned Action  
Embolic and thromboti
c 
events (SMQ)  previous medical hi
story of heart and embolic, 
thrombotic events  
Thrombocytopenia, 
leukopenia, and 
neutropenia  
 Thromb ocytopenia, 
leukopenia, and 
neutropenia  
 Careful monitor
ing of platelet counts is performed 
and in case platelet count s are <  50.000/mm3 
(< 50.0x109/L), the dose hold and/or dose de
crease 
guidance is to be fol
lowed.  
Additionally:  
â€¢ Monitoring of leukopen
ia and neutropenia 
as part of medica
l and periodic review  
â€¢ Monitoring of AEs and t
he medical history 
and concomitant medica
tions that may 
cause thrombocytopeni
a, leukopenia, and 
neutropenia  
AE = adverse event; AESI  = adverse event of
 special interest; ALP  = alkaline phosphatase; A
LT = alanine 
aminotransferase; AST  = aspartate aminotransf
erase; FSH  = follicle -stimulating hormo
ne; MedDRA  = Medical 
Dictionary for Reg
ulatory Activities; SMQ  = standardized MedDRA 
queries.  
Per the request of th
e European Heal th Authority, thr
ombocytopenia, leukopenia, and neutropenia were added as 
AESIs.  
8.5. Safety Assessment
s 
Planned time points for all safety assessme
nts are provided in Section  2, the SoE.  
8.5.1.  Physical Examinations  
â€¢ A full physical examination will include
, at a minimum, assessments of the 
cardiovascular, respi[INVESTIGATOR_696], ga
strointestinal, and neurological systems.  A full 
physical examination will be completed at the Scree
ning visit only.  
â€¢ A targeted physical examination will include, at a mini
mum, assessments of the 
cardiovascular and pulmonary systems and will
 be completed at all other visits after 
screening.  
â€¢ Investigators should pay special a
ttention  to clinical signs related to previous serious 
illnesses.  
8.5.2.  Vital Signs  
â€¢ Temperature, weight, pulse rate, r
espi[INVESTIGATOR_697], and BP will be assessed at every 
visit.  Height will be measured once, during the sc
reening period.  
â€¢ BP and pulse measurements will be
 assessed with a completely automated device 
while seated.  Manual techniques will be use
d only if an automated device is not 
available.  
â€¢ Vital signs should be taken before blood collection for
 laboratory tests.  BP and pulse 
measurements should be preceded b y approximately [ADDRESS_184761] for the 
participant in a quiet setting without distractions (e.g.,  television, cell phones) for the 
initial reading.  Blood pressure values should be confirmed by [CONTACT_159123] 2  readings 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184762]  2021 
Acceleron Pharma Inc.  Page 53 of 93 CONFIDENTIAL  obtained approximately 5 minutes apart.   The average of the BP
 readings will be 
recorded on the eCRF.  
â€¢ Clinically significant abnormal findi
ngs will be reported as AEs (see  Section  6.3 and 
Section  8.4). 
8.5.3.  Electrocardiograms  
â€¢ A 12 -lead ECG will be obtained as outlined in t
he SoE.  Parameters obtained will be 
HR, PR, QRS, and QT; QTcF  intervals  will be calculated.  If the ECG ma
chine does 
not automatically calculate QTcF, it shoul
d be manually calculated.  
â€¢ Clinically significant abnormal findi
ngs will be reported as AEs.  
â€¢ If scheduled on the same day, ECGs should be pe
rformed prior to 6MWT.  
8.5.4.  Clini cal Worsening  
â€¢ Clinical worsening will be assessed by [CONTACT_159124] (or at any other time at the 
Investigatorâ€™s discretion) and recorded on the eCRF.  
â€¢ Assessments are the following:  
âˆ’ Death  
âˆ’ Worsening -related listing for lung and/or heart tra
nsplant  
âˆ’ Need to initiate rescue th
erapy (see below), with an approved PAH SOC therapy  
âˆ’ Need for atrial septostomy  
âˆ’ PAH -specific hospi[INVESTIGATOR_059] (> 24 hours)  
âˆ’ Functional deterioration a
s defined by [CONTACT_159125], even if they began a
t different times, as compared to their Screening 
values:  
âˆ’ Worsened WHO functio
nal class (III to IV)  
and 
âˆ’ Decrease in 6MWD by â‰¥ 15% a
s compared to Screening (confirmed by [CONTACT_1192] 
6MWTs; Section  8.2.4 ) 
â€¢ Clinically significant abnormal findi
ngs will be reported a s AEs.  
8.5.5.  Rescue Therapy Cr
iteria  
Suggested clinical worsening crite
ria for the investigator to initiate rescue therapy with an 
approved PAH SOC thera
py (and therefore discontinue study drug) include the following:  
â€¢ Participants who experience wor
sening of PA H requiring hospi[INVESTIGATOR_159076] 24 hours.  
â€¢ PAH functional deterioration (w
orsening of WHO functional class by 1 level and a 
decrease in 6MWD of 15% a
s compared to Screening measured on 2 occasions).  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184763]  2021 
Acceleron Pharma Inc.  Page 54 of 93 CONFIDENTIAL  8.5.6.  Clinical Safety Laboratory Assessments  
â€¢ See Appendix  [ADDRESS_184764] of clinical laboratory t
ests to be performed and refer to the 
SoE for the timing and frequency.  
â€¢ If Hgb is â‰¥ 17 g/dL during Cycle 1 (Day 8) or Cyc
le 2 (Day 29), participants should 
return weekly for Hgb monitoring.  Clinica
lly significant abnormal Hgb findings will 
be reported as AEs.  Dose Modifica
tion Guidance should be followed (see  Figure  3). 
â€¢ Clinically significant abnormal Hgb findings wil
l be reported as AEs.   
â€¢ The investigator must review the laboratory re
port, document this review, and record 
any clinically relevant changes oc
curring during the study in the AE section of the 
eCRF.  The laboratory reports must be f
iled with the source documents.  Clinically 
significant abnormal laboratory findings are
 those which are not associated with the 
under lying disease, unless judged by [CONTACT_159126]'s condition.  
â€¢ All laboratory tests with values considered c
linically significantly abnormal during 
participation in the study or within [ADDRESS_184765] dose of study treatment 
should be repeated until the values return to normal or ba
seline or are no longer 
considered clinically signific
ant by [CONTACT_10982].  
âˆ’ If such values do not return to normal/baseline wit
hin a period of time j udged 
reasonable by [CONTACT_093], the eti
ology should be identified and the sponsor 
notified.  
âˆ’ All protocol -required laboratory assessments, as defined 
in Appendix  2, must be 
conducted in accordance with t
he laboratory manual and Section  2, SoE.  
âˆ’ If laboratory values from non -protocol -specified laboratory assessments 
performed at the institutionâ€™s loc
al laboratory require a change in participant 
management or are considere
d clin ically significant by [CONTACT_093] (
e.g., SAE 
or AE or dose modification), then the result
s must be recorded in the eCRF.  
8.6. Pharmacokineti
cs 
â€¢ Serum samples will be collec
ted for measurement of serum concentrations of 
sotatercept as specified in Section  2 SoE.  Instructions for the collection a
nd handling 
of biological samples will be provided by [CONTACT_456].  T
he actual date and time 
(24-hour clock ti me) of each sample will be re
corded.  
â€¢ Samples will be used to evaluate the PK of sot
atercept.  Samples collected for 
analyses of sotatercept serum c
oncentration may also be used to evaluate PK of other 
concomitant medications and safety or 
efficacy aspects related to concerns arising 
during or after the study.  
Participants who have already e
ntered the Extension Period under Protocol Amendment 3A 
(Q4W dosing regimen) should have a pr
e-dose PK sample taken at an unsc
heduled visit before 
transitioning to Q3W do sing under this amendment.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184766]  2021 
Acceleron Pharma Inc.  Page 55 of 93 CONFIDENTIAL  8.7. Pharmacodyna
mics  
Venous blood samples will be colle
cted for measurement of PD biomarkers including but not 
limited to NT -proBNP, transforming growth factor -Î²eta 1 (TGF -Î²1), vascular endothelial growth 
factor receptor (VEGFR
1), an d sex hormone metabolites N -terminal prohormone of brain 
natriuretic peptide (NT -proBNP), at time points listed in Section  2 SoE.   Samples collected for 
NT-proBNP analyses may also be used to evaluate safety or 
efficacy aspects related to concerns 
arising during or after the study.  
Transpulmonary Flux Biomarke
rs: Samples from the RHC and from the radial arte
ry will be 
collected at rest, peak e
xercise, and post -exercise during the iCPET proce
dure at the time points 
listed in the SoE and as described in t
he iCPET manual.  These samples will be stored and may 
be analyz ed at a later date for e
xploratory biomarkers.  
8.8. Genetic Testing  
Participants will have a geneti
c sample taken to assess the mutation status and allele frequency 
(e.g., BMPR2 ) at C1D1.  Since genetic mutations in BMPR2  are associated with PAH, this 
testing m ay provide insight into the genetic
 basis of PAH and potential response to sotatercept.  
Other potential genetic ana
lyses include, but are not limited to, activin receptor -like kinase 1, 
caveolin 1, eukaryotic translation i
nitiation factor [ADDRESS_184767] de
capentaplegic homolog 9; otherwise known as 
SMAD9.  See  Appendix  9 for more i nformation regarding genetic testing.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184768]  2021 
Acceleron Pharma Inc.  Page 56 of 93 CONFIDENTIAL  9. STATISTICAL CO
NSIDERATIONS  
9.1. Sample Size Determi
nation  
Assuming the change from baseline of pe
ak VO 2 is 1.5 mL/min/kg, with a standard deviation of 
3 mL/min/kg, the sample size nee
ded will be 19 participants with 1 -sided alpha=0.10 level and 
80% power.  This approximate level of im
provement in pulmonary hypertension patients has 
been associated with a 28 % decrease in PVR.11 
This sample size of 19 participants will also provide
 80% power to detect an increase from 
baseline of at least 10 mL i
n RV SV at 1 -sided alpha=0.[ADDRESS_184769] deviation 
of RV SV is 20  mL.  It is expected that a 10 -mL improvement in SV correlates wit
h an ability 
for the patient to walk and a
dditional 41  m on 6MWT in patients with PAH .12 
Assuming a 25% drop -out rate, approximately 25  participants will be enrolled.  
9.2. Populations f
or Analyses  
Evaluable Population: All participants who have 
completed the Treatment Per iod and had the 
iCPET assessment and cardiac MR im
aging at the [ADDRESS_184770] 
major impacts on the efficac
y of the study treatment.  
Safety Population: All participants who re
ceive at least 1 dose of study treatment.  
Pharmacokinetic Population: All parti
cipants who receive at least [ADDRESS_184771] 1 PK sample
 analyzed.  
9.3. Statistical 
Analyses  
The Statistical Analysis Plan (SAP) w
ill be developed and finalized before topline (24 weeks) 
database lock and will describe the a
nalysis details.  Data will be reviewed as needed to s upport 
regulatory filings.  This section is a sum
mary of the planned statistical analyses of the primary 
and key secondary endpoint
s.  A separate SAP for the extension period analysis will be 
developed and finalized be
fore the final database lock.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184772]  2021 
Acceleron Pharma Inc.  Page 57 of 93 CONFIDENTIAL  9.3.1.  Efficacy  Analyses  
Table  10: Statistical Analysis of Endpoints  
Endpoint  Statistical Analysis Methods  
Primary  The mean and standard deviation for change from baseline of peak VO 2 will be 
calculated together with the correspondin g 95% CI.  The evaluable population will be 
used for the primary endpoint analyses.  
Secondary  Descriptive statistics will be presented for secondary cardiac MR endpoints (RV SV, 
RV ESV, RV EDV, RV EF, RV SVI, and RV mass  by [CONTACT_159127]),  iCPET 
endpoints (VE/VCO 2, Ca-vO 2), PVR, 6MWD, and biomarker endpoint NT -proBNP.  
Frequency summaries will be provided for WHO functional class assessments and 
participants with clinical worsening.  Nonlinear mixed effects modeling will be 
employed to determine population PK parameters of sotatercept.  
Exploratory  Descriptive statistics will be presented for biomarker endpoint change from baseline in 
PAH -related biomarkers.  Change from baseline in selected primary and secondary 
endp oints during the 8 -week Follow -Up Period will be summarized through descriptive 
statistics.  Exercise hemodynamic measures will be summarized through descriptive 
statistics.  
Other 
Endpoints  In general, continuous data will be summarized descriptively for absolute values and 
change from baseline with n, mean, SD, median, minimum, maximum, and categorical 
data will be summarized with frequency and percentage.  
6MWD = six -minute walk distance; Ca -vO 2 = content difference, arteriovenous O 2; CI = confidence interval; 
iCPET  = invasive cardiopulmonary exercise test; MR = magnetic resonance; NT-proBNP = N -terminal prohormone 
of brain natriuretic peptide, PAH = pulmonary arterial hypertension; PK = Pharmaco kinetic; PVR  = pulmonary 
vascular resistance; RV = right ventricular; RV  EDV = right ventricular end -diastolic volume; RV  EF = right 
ventricular ejection fraction; RV  ESV = right ventricular end -systolic volume; RV  SV = right ventricular stroke 
volume; RV  SVI = right ventricular stroke volume index; SD = standard deviation; VE/VCO 2 = ventilator 
efficiency; VO 2 = peak O2 uptake ; WHO = World Health Organization  
Details will be described in the statistical analysis plan and finalized before database lock.  
9.3.2.  Safety Analyses  
All safety analyses will be performed on the Safety Population.  
Adverse events will be coded using Medical Dictionary for Regulatory Activities ( MedDRA). 
Adverse event listings will include the verbatim term and the MedDRA preferred term. 
Treatment -emergent AEs (TEAEs) will be summarized by [CONTACT_27711], system organ 
class, and preferred term.  TEAEs related to the IP will also be summarized.  TEAEs leading to 
death or discontinuation from treatment and serious TEAEs will be listed s eparately.  
Clinical laboratory results will be summarized descriptively for the Safety Population.  Clinically 
significant laboratory abnormalities will be flagged in the listing.  Shift tables will be presented 
for hematology, serum chemistry, and urinaly sis tests.  Renal function laboratory tests (creatinine 
and urine albumin creatinine ratio) will be collected regularly during the Treatment Period and 
may be limited to creatinine in the Extension Period.  The descriptive statistics (mean, SD, 
median, min , max) will be provided for each time point of the collection.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184773]  2021 
Acceleron Pharma Inc.  Page 58 of 93 CONFIDENTIAL  Vital sign measurements, ECG results, and physica
l examination data will be listed for each 
participant at each visit.  Descriptive
 statistics for vital signs and ECG parameters, both observed 
values and changes from baseline
, will be summarized.  
Immunogenicity (incidence/tite
r of ADA) will also be analyzed.  
9.3.3.  Other Analyses  
Pharmacokinetic, PD, and biomarker explor
atory analyses will be described in the statistical 
analysis plan finalized be
fore database lock.  
9.3.4.  Primary Endpoint An
alysis  
An analysis of the primary endpoint of change
 in VO 2 at 24 weeks Treatment Period (
Cycle 9) 
versus  the screening assessment will be perf
ormed on the evaluable population when all 
participants during the Treatment Pe riod have completed their 24 -week (Cycle 9) iCPET 
assessment or EOT iCPET for those subjects who 
discontinue early during the  Treatment Period, 
as described in  Section  9.3.[ADDRESS_184774] for the Extension Period as with the main 
analysis in the Treatment
 Period.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184775] 2015;148:[ADDRESS_184776] [ZIP_CODE]: ACTRIIA -Fc rebalanc
es BMP and 
activin/TGF -Î² signaling to attenua
te experimental pulmonary hypertension. Circulation 
2017; 2017;136(Suppl 1):A18906.  
3. Rubin LJ. Primary pulmonary hy
pertension. N Engl J Med 1997;336:111 -7. 
4. Simonneau G, Galie
 N, Rubin LJ, et al. Clinical classific
ation of pulmonary hypertension. 
J Am Coll Cardiol 2004;43:5 -12S. 
5. Schermuly RT, Ghofr
ani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary 
arterial hypertension. Na
t Rev Cardiol 2011;8:443 -55. 
6. Vonk -Noordegraaf A, Ha
ddad F, Chin KM, et al. Right heart ada
ptation to pulmonary 
arterial hypertension: ph
ysiology and pathobiology. J Am Coll Cardiol 2013;62:D22 -33. 
7. Morrell NW. P
ulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue 
remodeling? Proc Am Thorac Soc 2006;3:
680-6. 
8. Machado RD, Aldre
d MA, James V, et al. Mutations of the TGF -beta type II 
receptor 
BMPR2 in pulmonary arte
rial hypertension. Hum Mutat 2006;27:121 -32. 
9. Galie N, Humbert 
M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and 
treatment of pulmo nary hypertension: The
 Joint Task Force for the Diagnosis and 
Treatment of Pulmona
ry Hypertension of the European Society of Cardiology (ESC) and 
the European Respi[INVESTIGATOR_159077] (ERS): Endorsed by: [CONTACT_159128] C
ongenital Cardio logy (AEPC), Interna
tional Society for Heart and Lung 
Transplantation (ISHL
T). Eur Heart J 2016;37:[ADDRESS_184777]. 
Circulation 2013;127:1157 -64. 
11. Lewis GD, Shah R
V, Pappagianopolas  PP, et al. De
terminants of ventilatory efficiency in 
heart failure: the 
role of right ventricular performance and pulmonary vascular tone. Circ 
Heart Fail 2008;1:[ADDRESS_184778] 2011;139:1003 -9. 
13. Forfia PR, F
isher MR, Mathai SC, et al. Tricuspid annular displa
cement predicts survival 
in pulmonary hypertension. Am J Respir C
rit Care Med 2006;174:1034 -41. 
14. Gabler NB, Frenc
h B, Strom B L, et al. Valida
tion of 6 -minute walk distance
 as a surrogate 
end point in pulmonary arterial hyper
tension trials. Circulation 2012;126:[ADDRESS_184779]. Am J R
espir Crit Care 
Med 2003;167:1287.  
16. ATS State ment. Guidelines for 
the Six -Minute Walk Test. Am 
J Crit Care 2002;166:111 -7. 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184780]
ers T, et al. An official European Respi[INVESTIGATOR_16362]/American Thorac
ic Society technical standard: field walking tests in chronic 
respi[INVESTIGATOR_159078]. Eur Respir J 2014;44(6):1428 -46. 
18. Guidance for Industry, 
Investigators, and Institutional Review Boards: FDA Guidance on 
Conduct of Clinical 
Trials of Medical Products during COVID -19 Pandemic. U.S. 
Department of Hea
lth and Human Services Food and Drug Administration Center 
for 
Drug Evaluation and Re
search (CDER) and the Center for Biologics Evaluation and 
Research (CBER). Ma
rch 2020 (updated 16 April 2020).  
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184781]  2021 
Acceleron Pharma Inc.  Page 61 of 93 CONFIDENTIAL  11. APPENDICES  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184782] Computed tomography  
CTPA  Computed tomography pulmonary angiogram  
Ctrough Minimum concentration before dosing  
CxDy  Cycle x Day y  
DBP  Diastolic blood pressure  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
EF Ejection fraction  
EOS  End of study  
EOT  End of treatment  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184783]  
FC Functional classification  
FDA  Food and Drug Administration  
FEV 1 Forced expi[INVESTIGATOR_3741] 1 second  
FSH Follicle -stimulating hormone  
FVC  Forced vital capacity  
GCP  Good Clinical Practice  
Hgb Hemoglobin  
HR Heart rate  
HRT  Hormone replacement therapy  
IB Investigatorâ€™s brochure  
ICF Informed consent form  
ICH International Council for Harmonisation  
iCPET  Invasive cardiopulmonary exercise test  
IEC Independent ethics committee  
IgG1  Immunoglobulin G1  
IP Investigational product  
IRB Institutional review board  
IUD Intrauterine device  
IV Intravenous  
LV Left ventricular  
MedDRA  Medical Dictionary for Regulatory Activities  
MR Magnetic resonance  
NOAEL  no-observed -adverse -effect level  
NCI-CTCAE  National Cancer Institute -Common Terminology Criteria for Adverse 
Events  
NT-proBNP  N-terminal prohormone of brain natriuretic peptide  
PA Pulmonary artery  
PAH  Pulmonary arterial hypertension  
PAP Pulmonary arterial pressure  
PCWP  Pulmonary capi[INVESTIGATOR_159079]5  Phosphodiesterase type 5  
PK Pharmacokinetic  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184784] Term  Explanation  
[COMPANY_003] [COMPANY_003] Safety Hotline, medical monitor for this study  
PVR  Pulmonary vascular resistance  
Q3W  Every 3 weeks  
Q4W  Every 4 weeks  
Qp/Qs  Pulmonary -Systemic Flow Ratio  
RA Right atrial  
RAP  Right atrial pressure  
RBC  Red blood cell  
RHC  Right heart catheterization  
RV Right ventricular  
RV EDV  Right ventricular end-diastolic volume  
RV EF Right ventricular ejection fraction  
RV ESV  Right ventricular end -systolic volume  
RV PA Right ventricular pulmonary artery  
RV SV Right ventricular stroke volume  
RV SVI Right ventricular stroke volume index  
SBP Systolic blood pressure  
SAE  Serious adverse event  
SC Subcutaneous(ly)  
SD Standard deviation  
SOC  Standard of care  
SoE Schedule of Events  
SSFP  Structure and Function Sequences  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
SV Stroke volume  
SVC  Superior vena cava  
TEAE  Treatment -emergent adverse event  
TGF -Î² Transforming growth factor -beta 
UA Urinalysis  
UACR  Urine albumin creatinine ratio  
ULN  Upper limit of normal  
VAF  Variant allele frequency  
VE/VCO 2 Ventilator efficiency  
Venc  Velocity encoding (cardiac motion view via MRI)  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184785] Term  Explanation  
VO 2 max Peak O 2 uptake  
VQ Ventilation -perfusion  
VSMC  Vascular smooth muscle cell  
WHO  World Health Organization  
WOCBP  Woman of childbearing potential  
 
082WBL
Clinical Study Protocol  Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184786]  2021 
Acceleron Pharma Inc.  Page 66 of 93 CONFIDENTIAL  APPENDIX  2. CLINICAL LABOR
ATORY TESTS  
The tests detailed in Table  11 will be performed by [CONTACT_159129] (SoE, Section  2). 
Additional tests may be performed 
at any time during the study as determined necessary by [CONTACT_41161]
. 
Table  11: Protocol -Required Safety Labor
atory Ass essments  
Laboratory Assessments  Parameters  
Hematology  Complete blood count (
CBC) with differential: CBC includes RBCs, 
white blood cells (
WBCs), platelets, hemoglobin, hematocrit, mean 
corpuscular volum
e (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobi
n concentration (MCHC), reticulocyte count, and 
platelet count  
Serum chemistry  Albumin, alkaline ph
osphatase (ALP), ALT, AST, blood urea nitrogen 
(BUN), calcium
, chloride, carbon dioxide, creatinine, glucose, 
phosphorus, potassium, sodium,
 total bilirubin, direct bilirubin  
Urinalysis  Urinalysis  
ALP  = alkaline phosphatase; 
ALT  = alanine aminotransf
erase; AST  = aspartate aminotransf
erase; CBC  = complete 
blood count; C
R = creatinine; Hgb  = hemoglobin; Hct  = hematocrit; RBC  = red blood cel
l; WBC  = white blood cell  
Investigators must document their r
eview of each laboratory safe
ty report.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184787] 2 agents (each from 
a different class) from a list
 including the following: an  ERA, a PDE5 inhibitor, a soluble 
guanylate cyclase stimulator, a
nd/or a prostacyclin analogue or receptor agonist.  
Standard of Care should remain st
able throughout the study.  Small adjustments or titrations are 
routine SOC for PAH therapi[INVESTIGATOR_13265] a
re considered stable dosing.  If a particip ant has an event of 
clinical worsening requiring resc
ue therapy (see  Section  8.5.5 ), SOC therapy may be alter
ed as 
per the treating physicianâ€™s dec
ision, and the participant will be discontinued from study dr
ug 
treatment.  Any other changes (a
side from rescue therapy for clinical worsening) to a 
participantâ€™s SOC should be discussed with the medic
al monitor on a case -by-case basis to 
determine if the par ticipant may stay on study trea
tment.  
During the Extension Period, parti
cipants under investigatorâ€™s supervision can subst
itute, 
remove, or adjust the dose of SOC for PAH -worsening and chronic concomita
nt medications, 
including supplemental oxygen.  Invest igator discretion will be used to determine if sotate
rcept 
study drug discontinuation is necessar
y.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184788] surface that is seldom traveled.  The walking course should 
prefera bly be 30 m in length.  The length of the corridor should be mark
ed every 3 m.  The 
turnaround points should be marked (e.g., with a 
cone).  A starting line, which marks the 
beginning and end of each 60 -m lap, should be marked on the floor (e.g., us
ing bri ghtly colored 
tape).  
The 6MWD will be calculated and re
corded. If the participant discontinues the test prematurely, 
the time (mm:ss) and distance walked w
ill be recorded.  Requirement of acute supportive rescue 
medication (e.g., oxygen therapy) a
nd any AE s occurring during the 6MWT will be r
ecorded.  If 
a participant is on chronic oxygen thera
py, oxygen should be given at their standard rate or as 
directed by [CONTACT_093].  During the study, the 6MWT should be done
 about the same time of 
day to avoid d iurnal variation.  
Required Equip
ment  
1. Countdown timer (or stopwatch)  
2. Mechanical lap counter  
3. Two small cones to mark the tur
naround points  
4. A chair that can be easil
y moved along the walking course  
5. Worksheets on a clipboard  
6. A source of oxygen  
7. Sphygmomanomete r 
8. Telephone  
9. Automated electronic defibrillator  
10. Portable pulse oximeter  
Participant Preparatio
n 
1. Comfortable clothing should be worn.  
2. Appropriate shoes for walking should be
 worn.  
3. Participants should use their usual walking a
ids during the test (cane, walker , etc.).  
4. The participant's usual medical regimen shoul
d be continued.  
5. A light meal is acceptable be
fore early morning or early afternoon tests.  
6. Participants should not have exercised vigorously 
within [ADDRESS_184789].  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184790] ing should be performed about the same time of day to minimize intraday 
variability.  
2. A "warm -up" period before the test should not be performed.  
3. The participant should sit at rest in a chair, located near the starting position, for at least 
[ADDRESS_184791] baseline HR and oxygen saturation (SpO 2) and follow manufacturer' s 
instructions to maximize the signal and to minimize motion artifact.  
5. Make sure the readings are stable before recording.  Note pulse regularity and whether 
the oximeter signal quality is acceptable.  
Instruct the participant as follows:  
"The object of this test is to walk as far as possible for [ADDRESS_184792] without hesitation.  Now I'm going to show you.  Please watch 
the way I turn without hesitation."  
Demonstrate by [CONTACT_114037].  Walk and pi[INVESTIGATOR_113988] a cone briskly.  
"Are you ready to do that?  I am going to use this counter to keep track of the number of laps you 
complete.  I will click it each time you turn around at this starting line.  Remember that the 
object is to walk AS FAR AS POSSIBLE for 6 minutes, but don't run or jog.  Start now, or 
whenever you are ready."  
1. Position the particip ant at the starting line.  You should also stand near the starting line 
during the test.   Do not walk with the participant.  As soon as the participant starts to 
walk, start the timer.  
2. Do not talk to anyone during the walk.  Use an even tone of voice when using the 
standard phrases of encouragement.  Watch the participant.  Do not get distracted and 
lose count of the laps.  Each time the participant returns to the starting line, click the lap 
counter once (or mark the lap on the worksheet).  Let the partici pant see you do it. 
Exaggerate the click using body language, like using a stopwatch at a race.  
After the first minute, tell the participant the following (in even tones): "You are doing well.  
You have 5 minutes to go."  
When the timer shows 4 minutes rema ining, tell the participant the following: "Keep up the good 
work.  You have 4 minutes to go."  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184793]  2021 
Acceleron Pharma Inc.  Page 70 of 93 CONFIDENTIAL  When the timer shows 3 minutes remaining, tell the participant the following: "You are doing 
well.  You are halfway done."  
When the timer shows 2 minutes remaini ng, tell the participant the following: "Keep up the good 
work.  You have only 2 minutes left."  
When the timer shows only 1 minute remaining, tell the participant: "You are doing well.  You 
have only 1 minute to go."  
Do not use other words of encouragement  (or body language to speed up).  
If the participant stops walking during the test and needs a rest, say this: "You can lean against 
the wall if you would like; then continue walking whenever you feel able."  Do not stop the 
timer.  
If the participant stops before the 6 minutes are up and refuses to continue (or you decide that 
they should not continue), wheel the chair over for the participant to sit on, discontinue the walk, 
and note on the worksheet the distance, the time stopped, and the reason for stoppi [INVESTIGATOR_113989].  
When the timer is 15 seconds from completion, say this: "In a moment I'm going to tell you to 
stop.  When I do, just stop right where you are and I will come to you."  
When the timer rings (or buzzes), say this: "Stop!"  Walk over to the par ticipant.  Consider 
taking the chair if they look exhausted.  Mark the spot where they stopped by [CONTACT_1299] a bean bag 
or a pi[INVESTIGATOR_113990].  
Post-test:  
1. Measure SpO [ADDRESS_184794] the additional distance covered (the number of meters in the final partial lap) 
using the markers on the wall as distance guides.  
4. Calculate the total distance walked, rounding to the nearest meter, and record it on the 
worksh eet. 
5. Congratulate the participant on good effort and offer a drink of water.  
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184795]  
Right Heart Catheterization  
Resting supi[INVESTIGATOR_159080].  Zero -pressure 
calibration will be performed at the mid -axillary line with the patient in a supi[INVESTIGATOR_2547].  SVC, 
RA, RV, PCW, and PA pressures will be measured, and mean vascular pressures will be 
calculated based on systolic and diastolic pressure measurements.  Heart rate and vascular 
pressures are monitored continuously.  Cardiac output is measured by [CONTACT_159130].  Di astolic 
and transpulmonary pressure gradients are obtained, systemic and PVRs are calculated.   
Physiologic Measurements: iCPET  
Maximum symptom -limited incremental iCPET is performed using an upright cycle ergometer 
and a breath -by-breath metabolic cart wi th subjects breathing room air.  
Minute ventilation, breath -by-breath pulmonary gas exchange, HR, radial arterial BP, RAP, RV 
pressure, and PAP are measured throughout the test.  PAWP is obtained at rest and at the end of 
each minute of exercise.   
By [CONTACT_3252] -oximetry, oxygen saturation, Hgb concentration, and O 2 content (C aO2 and C vO2, 
respectively) are measured for each blood sample.  CO is then calculated by [CONTACT_159131] a simultaneously measured VO 2.  Predicted CO MAX was calculated from predicted VO 2MAX  
and an assumed maximal arterial -mixed venous O 2 content difference equivalent to a normal 
(Hgb) of 14 g/dL for healthy subjects.  
The full iCPET guideline will be included in a separate charter.  
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184796] images, 
and the capability to transmit cardiac MR images for central reader review are validated for 
qualification.  Only sites who are prequalified by [CONTACT_159132].  The quality of site cardiac MR imaging is  continually monitored to 
maintain consistency and minimize variability throughout the study.  A study -specific cardiac 
MR imaging manual in agreement with the imaging charter will be provided for consistency in 
imaging performance, reporting format, and i mage transmission.  
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184797]  2021 
Acceleron Pharma Inc.  Page 73 of 93 CONFIDENTIAL  APPENDIX  7. STUDY GOVERNANCE CONSIDERATIONS  
Regulatory and Ethical Considerations  
â€¢ This study will be conducted in accordance with the protocol and with the following:  
âˆ’ Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
âˆ’ Applicable ICH Good Clinical Practice (GCP) Guidelines  
âˆ’ Applicable laws and regulations  
â€¢ The protocol, protocol amendments, ICF, Investigatorâ€™s Brochure (IB), and other 
relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_52009]/IEC before the study is initiated.  
â€¢ Any amendments to the protocol will require IRB/IE C approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
â€¢ The investigator will be responsible for the following:  
âˆ’ Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
âˆ’ Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
âˆ’ Providing ove rsight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations  
Informed Consent Process  
â€¢ The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study.  
â€¢ Participants must be informed that their participation is voluntary.  Participants will 
be required to sign a state ment of informed consent that meets the requirements of 
[ADDRESS_184798] (HIPAA) requirements, where applicable, and the IRB/IEC or 
study center.  
â€¢ The medical record must inclu de a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must 
also sign the ICF.  
â€¢ Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184799]  2021 
Acceleron Pharma Inc.  Page 74 of 93 CONFIDENTIAL  â€¢ A copy of the ICF(s) must be provided to the participant or the participantâ€™s legally 
authorized representative.  
Data Protection  
â€¢ Participants will be assigned a unique identifier by [CONTACT_456].  Any participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable 
will not be transferr ed. 
â€¢ The participant must be informed that his/her personal study -related data will be used 
by [CONTACT_10999].  The level of disclosure 
must also be explained to the participant.  
â€¢ The participant must be informed tha t his/her medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
Publication Policy  
â€¢ All information concerning sotatercept is considered confidential and shall remain the 
sole property of the sponsor.  The investigator agrees to use this information only in 
conducting the study and shall not use it for any other purposes without the spons orâ€™s 
written approval.  The investigator agrees not to disclose the sponsorâ€™s confidential 
information to anyone except to persons involved in the study that need such 
information to assist in conducting the study, and then only on like terms of 
confidenti ality and non -use. 
â€¢ It is understood by [CONTACT_159133], 
and therefore may be disclosed as required to regulatory agencies .  To allow for the 
use of the information derived from clinical studies, it is understood that there is an 
obligation to provide the sponsor with complete test results and all data developed in 
the study.  
â€¢ No publication or disclosure of study results will  be permitted except as specified in a 
separate, written, agreement between the sponsor and the investigator.  
â€¢ The sponsor will comply with the requirements for publication of study results.  In 
accordance with standard editorial and ethical practice, the s ponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data.  In this case, a coordinating investigator [INVESTIGATOR_9231].  
â€¢ Authorship will be determined by [CONTACT_159134] d in line with International 
Committee of Medical Journal Editors authorship requirements.  
Data Quality Assurance  
â€¢ All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee electro nically (e.g.,  laboratory data).  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184800] 
by [CONTACT_1189].  
â€¢ The investigator must maintain accurate documentation (source data) that supports 
the information entered in the eCRF.  
â€¢ The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
â€¢ The sponsor or designee is responsible for the data mana gement of this study 
including quality checking of the data.  
â€¢ Study monitors will perform ongoing source data verification as indicated to confirm 
that data entered into the eCRF by [CONTACT_1191], complete, 
and verifiable from sourc e documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
â€¢ Recor ds and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_1732] [ADDRESS_184801], unless local regulations or institutional 
policies require a longer retention period.  No records may be destroyed during the 
retention period without the written approval of the sponsor.  No records may be 
transferred to another locati on or party without written notification to the sponsor.  
Source Documents  
â€¢ Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed at the 
investigatorâ€™s site.  
â€¢ Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained.  The investigator may need to request previous medical records or transfer 
record s, depending on the study.  Also, current medical records must be available.  
Study and Site Closure  
The sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the sponsor.  St udy sites will be closed upon study 
completion.  A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184802]  2021 
Acceleron Pharma Inc.  Page 76 of 93 CONFIDENTIAL  â€¢ Failure of the investigator to  comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
â€¢ Inadequate recruitment of participants by [CONTACT_093]  
â€¢ Discontinuation of further study treatment development  
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184803]  2021 
Acceleron Pharma Inc.  Page 77 of 93 CONFIDENTIAL  APPENDIX  8. CONTRACEPTI
VE GUIDANCE AND COLLECTION OF 
PREGNANCY INF
ORMATION  
Definitions  
Woman of Childbearing Pot
ential (WOCBP)  
A woman is considered fertile following mena
rche and until becoming postmenopausal unless 
permanently sterile (see 
below).  
Women in the follo wing categories are not 
considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the f
ollowing:  
â€¢ Documented hysterectomy  
â€¢ Documented bilateral salpi[INVESTIGATOR_1656]  
â€¢ Documented bilateral oophorectomy  
Note: Documentation can come from the site personne
lâ€™s review o f the participantâ€™s medical 
records, medical examinati
on, or medical history interview.  
3. Postmenopausal female  
â€¢ A postmenopausal state is defined as no m
enses for 12 months without an alternative 
medical cause.  A high FSH level in the postmenopa
usal range m ay be used to 
confirm a postmenopausal state in women not using hormonal contr
aception or 
hormone replacement therapy (HRT).  
However, in the absence of 12 months of 
amenorrhea, a single FS
H measurement is insufficient.  
â€¢ Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non -hormonal highly effective contrac
eption methods if they wish to continue 
their HRT during the study.  Otherwise, they must disc
ontinue HRT to allow 
confirmation of postmenopausal status befor
e study  enrollment.  
Contraception Guidance  
Male Participants  
Male participants with female partners of chil
dbearing potential are eligible to participate if they 
agree to ONE of the following (during the protoc
ol-defined time frame in Section  5.1): 
â€¢ Are abstinent from penile -vaginal intercourse as their usual and pre
ferred lifestyle 
(abstinent on a long -term and persistent basis) and agree
 to remain abstinent  
â€¢ Agree to use a male condom when having penile -vaginal intercourse with a WOCBP  
who is not currently pregnant  
Men with a pregnant or breastfeeding par
tner must agree to remain abstinent from penile/vaginal 
intercourse or use a male condom  during each epi[INVESTIGATOR_159081] [ADDRESS_184804] dose of study treatment.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184805] dose of study treatm
ent. 
Table  12: Highly Effective Contrace
ptive Methods  
Highly Effective Con
traceptive Methods That Are User Dependent1 
Failure rate of <  1% per year when used 
consistently and correctly  
Combined (estrogen and pr
ogestogen containing) hormonal contraception associated with inhibition of 
ovulation2 
â€¢ Oral 
â€¢ Intravaginal  
â€¢ Transdermal  
Progestogen only hormonal
 contraception associated with inhibition of ovulation  
â€¢ Oral 
â€¢ Injectable  
Highly Effective 
Methods That Are User Independent1 
Implantable proges
togen only hormonal contraception associated with inhibition of ovulation2 
â€¢ Intrauterine device
 (IUD)  
â€¢ Intrauterine hormon
e-releasing system (I
US) 
Bilateral tub
al occlusion  
Vasectomized Partner  
A vasectomized part
ner is a highly effective contraception method provided that the partner is the sole 
male sexual partner
 of the WOCBP and the absence of sperm has been confirmed.  If not, an additional 
highly effective m
ethod of contraception should be used.  
Sexual Abstinence  
Sexual abstinence is consider
ed a highly effective method only if defined as refraining from 
heterosexual intercou
rse during the entire period of risk associated with the study treatment.  The 
reliability of se
xual abstinence need s to be evaluated in re
lation to the duration of the study and the 
preferred and usual life
style of the participant.  
[ADDRESS_184806] dose of study tre atment.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184807]  2021 
Acceleron Pharma Inc.  Page 79 of 93 CONFIDENTIAL  Pregnancy Testing  
â€¢ WOCBP should only be included in the study after two c
onfirmed negative 
pregnancy tests.  
â€¢ Additional pregnancy testing should be pe
rformed prior to study drug administration 
at each dosing visit during the study as re
quired locally . 
Pregnancy testing will also be pe
rformed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.  
Collection of Pregnancy In
formation  
Male Participants with Par
tners Who Become Pregnant  
â€¢ The investigator will attempt to collect pregn ancy information on any male 
participantâ€™s female partner who be
comes pregnant while the male participant is in 
this study.  
â€¢ After obtaining the necessary signe
d informed consent from the pregnant female 
partner directly, the investiga
tor will record pregn ancy information on the appropriate 
form and submit it to the sponsor within 24 hours of learning of
 the partnerâ€™s 
pregnancy.  The female pa
rtner will also be followed to determine the outcome of the 
pregnancy.  Information on the status of the mother and child will be forwarded to the
 
sponsor.  Generally, the follow -up will be no longer than 6 to 8  weeks following the 
estimated delivery date.  Any termina
tion of the pregnancy will be reported regardless 
of fetal status (presence o
r absence of anomalies) or  indication for the procedure
. 
Female Participants Who Bec
ome Pregnant  
â€¢ The investigator will collect pregnanc
y information on any female participant who 
becomes pregnant while partic
ipating in this study.  Information will be recorded on 
the appropriate fo rm and submitted to the sponsor within 24 hours of learni
ng of a 
participant's pregnancy.  The partic
ipant will be followed to determine the outcome of 
the pregnancy.  The investigator w
ill collect follow -up information on the participant 
and the neonate a nd the information will be forwarded to the sponsor.  G
enerally, 
follow -up will not be required for longer than 6 to 8 we
eks beyond the estimated 
delivery date.  Any terminati
on of pregnancy will be reported, regardless of fetal 
status (presence or absen
ce of anomalies) or indicati
on for the procedure.  
â€¢ While pregnancy itself is
 not considered to be an AE or SAE, any pregnancy 
complication or elective t
ermination of a pregnancy will be reported as an AE or 
SAE.  A spontaneous abortion is always c
onsidered to be an SAE and will be reported 
as such.  Any po st-study pregnancy related S
AE considered reasonably related to the 
study treatment by [CONTACT_093] w
ill be reported to the sponsor as described in 
Section  8.3.10 .  While the investigator is not obliga
ted to actively seek this 
information in former study participants, he or she
 may learn of an SAE through 
spontaneous reporting.  
â€¢ Any female participant who becomes pr
egnant while participating in the st udy will 
discontinue study treatment.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184808]  2021 
Acceleron Pharma Inc.  Page 80 of 93 CONFIDENTIAL  APPENDIX  9. GENETICS  
Use/Analysis of DNA  
â€¢ Genetic variation may impact a participantâ€™s response to therapy, susceptibility to, 
and severity and progression of disease.  Variable response to therapy may be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mec hanism of action of the drug; disease etiology; and/or molecular 
subtype of the disease being treated.  
â€¢ DNA  samples will be used for research related to PAH.  They may also be used to 
develop tests/assays including diagnostic tests related to sotatercept a nd PAH.  
Genetic research may consist of the analysis of one or more candidate genes or the 
analysis of genetic markers throughout the genome (as appropriate).  
â€¢ DNA  samples will be analyzed for BMPR2  (and other potential genes of interest) 
mutational status  and variant allele frequency (VAF) at baseline . 
â€¢ The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to sotatercept or study treatments of this class to understand 
study disease or related conditions.  
â€¢ The results of genetic analyses may be reported in the clinical study report or in a 
separate study summary  and may be shared with regulatory authorities such as the 
Food and Drug Administration and the European Medicines Agency . 
â€¢ The sponsor will store th e DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184809]  2021 
Acceleron Pharma Inc.  Page 81 of 93 CONFIDENTIAL  APPENDIX  10. PROTOCOL AMENDMENT HISTORY  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.   
Substantive  changes from Protocol Amendment 3A (31 October 2019) to Protocol 
Amendment  04 (18 June 2020 ) are detailed below.  Minor edits are not included.  
Table  13: Protocol Amendment 03A to Protocol Amendment [ADDRESS_184810] ory 
Protocol Location  Description of Change  Brief Rationale  
Cover Page  Added:  
PROTOCOL AMENDMENT 04 
Dated 18 June 2020  This is the protocol amendment 
identifier and release date.  
Section  3.6, Benefit/Risk 
Assessment  In prior sotatercept  clinical 
oncology studies in chemotherapy -
induced anemia and osteolytic bone 
disease in multiple myeloma, 
leukopenia, neutropenia (including 
febrile neutropenia), 
granulocytopenia, and 
thrombocytopenia have been 
described as TEAEs.  As a 
consequence of th e decrease in 
WBCs, infection maybe a potential 
risk and, as a consequence of 
thrombocytopenia, bleeding may be 
a potential risk.  Per health 
authority request, leukopenia, 
neutropenia, and thrombocytopenia 
have been identified as AESIs in 
this study (see Section 6.3, Dose 
Modification and Section 8.3, 
Adverse Events).  The language regarding risks added 
to better synchronize between 
information presented in the IB and 
information presented in the ICF.  
Section 1 , Synopsis  
Table 4,  Schedule of 
Events: Extens ion and 
Follow -Up Periods  
Section  3.4.2 , Extension 
Period  
Figure 1 , Study Design  Dosing in the Extension Period was 
changed from every 4 -week dosing 
to every 3 -week dosing.  Q3W is selected to be consistent 
with PULSAR OLE and Phase 3 
A011 -11 study.   
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184811]  2021 
Acceleron Pharma Inc.  Page 82 of 93 CONFIDENTIAL  Table  13: Protocol Amendment 03A to Protocol Amendment [ADDRESS_184812] of 
Care Therapy  Added: â€œDuring the Extension 
Period, participants under 
investigatorâ€™s supervision can 
substitute, remove, or adjust the 
dose of SOC for PAH -worsening 
and chronic concomitant 
medications, including 
supplemental oxygen.  Investigator 
discretion will be used to determine 
if sotatercept study drug 
discontinuation is necessary.â€   This revision allows the investigator 
to use his clinical judgement during 
this extended period of study 
treatment in an open -label setting.  
 
Section  1, Synopsis  
Section  4.7.12 , Extension 
Period  
Section  4.8.1 , Treatment 
Extension Period  Upon completion of the study 
participants will be provided the 
opportunity to transition into a 
future long -term follow -up study.  This open -label study permits 
participants in the extension period 
of this study to continue sotatercept 
therapy after the completion of this 
clinical study.  
Section  5, Study 
Population  Added: â€œ Prospective approval of 
protocol deviations to recruitment 
and enrollment criteria, also known 
as protocol waivers or exemptions, 
is not permitted, unless within the 
FDA Guidance o n Conduct of 
Clinical Trials of Medical Products 
during COVID -19 Pandemic 
Guidance for Industry, 
Investigators, and Institutional 
Review Boards; March 2020 (FDA 
2020).â€  To align with sotatercept clinical 
programs and the new COVID -19 
guidelines.  
Section  6.2, Treatment 
Administration and 
Schedule  Added: â€œWhere rounding the 
weight and total volume is 
necessary, please refer to the 
Pharmacy Manual for further 
details.â€  This has been a common question 
clinical sites have asked 
Pharmaceutical Product 
Development ([COMPANY_003]) to clarify.  
Section  6.3, Dose 
Modification  Dose modification â€˜rulesâ€™ were 
revised to guidance.  
Hgb and platelet guidance were 
revised after revi ewing safety data Safety monitoring due to ongoing 
patient review and an extended 
1-year duration in study drug.  
AESIs, including leukocytopenia, 
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184813]  2021 
Acceleron Pharma Inc.  Page 83 of 93 CONFIDENTIAL  Table  13: Protocol Amendment 03A to Protocol Amendment [ADDRESS_184814] been 
administered sotatercept.  AEs and 
blood pressure guidance were 
removed from this section and 
moved to Section  8.3 and 
Section  8.4.  Regarding the 
monitoring of identified, potential, 
risks and AESI the manag ement of 
leukocytopenia, neutropenia and 
thrombocytopenia AESI were 
added per safety review decisions.  neutropenia, and thromb ocytopenia 
will continue to be monitored.  
Safety monitoring guidance on 
these items can be found in 
Section  8.4, which covers the 
monitoring of identified, potential, 
and AESIs.  
  
Section  7.1, 
Discontinuation  
Section  7.2, Withdrawal 
from Study  Removed â€œ loss of treatment 
effectâ€™â€™.  At this time, the effect is not known, 
and the effect cannot be defined.  
Therefore, the reference to the loss 
of treatment effect has been deleted.  
Section  8.2.3,  Pulmonary 
Vascular resistance by 
[CONTACT_159135]  2, Schedule of 
Events  Added hemodynamic variables  
â€¢ Systolic pulmonary artery 
pressure  
Diastolic pulmonary artery pressure  These were added following safety 
review.  
Section  8.3, Adverse 
Event  Further defined the following:  
Unexpected AE: updates below are 
indicated in bold font)  
An unexpected AE is an AE that, 
the nature, severity, specificity,  or 
outcome of which, is not consistent 
with the summary of  product 
characteristics  described in the IB 
under the Reference Safety 
Information.  
SAE: Hospi[INVESTIGATOR_159082]: A hospi[INVESTIGATOR_159083]:  Updated according to the reporting 
requirements for safety monitoring, 
and ICH Topic E 2: A Clinical 
Safety Data Management.  
 
Added the word â€œ specificity â€™â€™ to 
align with GCP guidance .and the 
summary of product characteristics 
to be use d only for the marketed 
product.  
 
Updated according to Definitions 
and Standards for Expedited 
Reporting, and AESI and SAE 
requirements.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184815]  2021 
Acceleron Pharma Inc.  Page 84 of 93 CONFIDENTIAL  Table  13: Protocol Amendment 03A to Protocol Amendment [ADDRESS_184816] ory 
Protocol Location  Description of Change  Brief Rationale  
Updated safety monitoring moved 
AESIs to Section 8.4 . 
Deleted other ir relevant materials.  
Section 8.3.8 , Overdose  Specified the definition of 
Overdose for sotatercept  dosing 
based on weight.  Added to the definition of overdose 
and recently standardize language 
from Acceleron PAH clinical 
programs.  
Section 8.3.9 , 
Transmission of an 
Infectious Agent  Added language in the case that a 
virus or infectious particle, 
patho genic or non -pathogenic, is 
considered an infectious agent, in 
addition to instructions for 
reporting within 24  hours.  Preparation for an infectious disease 
during the study.  
Section 8.3.10 , 
Pregnancy  Removed: Any infant death that is 
assessed as possibl y related to the 
in utero exposure to sotatercept 
therapy should be reported as an 
SAE.  Removal is reflective of ICH safety 
reporting for pregnancy.  
Section 8.[ADDRESS_184817] sotatercept 
patientâ€™s AESIs are necessary to 
assess the overall safety of the PAH 
patient population; therefore, a 
detail section for safety monitoring 
AESIs was added to this sotatercept 
clinical study.  
Section 9.3.[ADDRESS_184818] a separate 
statistical analysis plan (SAP).  
Section 9.3.4,  Primary 
Endpoint Analysis  Added: An analysis of the primary 
endpoint of change in VO 2 at 
24 weeks Treatment Period 
(Cycle  9) versus the screening This addition gives further 
clarification of the Primary 
Endpoint Analysis.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184819]  2021 
Acceleron Pharma Inc.  Page 85 of 93 CONFIDENTIAL  Table  13: Protocol Amendment 03A to Protocol Amendment [ADDRESS_184820] completed their 
24-week (Cycle  9) iCPET 
assessment or EOT iCPET for those 
subjects who discontinue early 
during the Treatment Period, as 
described in  Section 9.3.1 . 
Appendix 10 , Protocol 
Amendment History  Moved the Protocol Amendments 
02 and 03A history from the 
Summary of Changes section to 
Appendix 10 . Amendment history was provided 
for Protocol Amendment 04 in the 
Summ ary of Changes section and 
was moved to  Appendix 10.  
  
082WBL
&OLQLFDO6WXG\3URWRFRO  6 RWDWHUFHSW$&(
6WXG\1R$5HYLVLRQ
$XJXVW
$FFHOHURQ3KDUPD,QF 3DJHRI &21),'(17,$/6XEVWDQWLYHFKDQJHVIU RP3URWRFRO$PHQGPHQW'HFHPEHU WR3URWRFRO
$PHQGPHQW$2FWREHUDUHGH WDLOHGEHORZ0LQRUHGLW VDUHQRWLQFOXGHG
7DEOH 3URWRFRO$PHQGPHQWW R3URWRFRO$PHQGPHQW$$PHQG PHQW+LVWRU\
3URWRFRO/RFDWLRQ 'HVFULSWLRQRI&KDQJH %ULHI5DWLRQDOH
7DEOHSDJH  0HGLFDOPRQLWRUKDVFKDQJHGIURP
WR ZKR
ZLOODOVRSHUIRUPVDIHW\PRQLWRULQJ &KDQJHLQDVVLJQPHQWVDQG
UHVSRQVLELOLWLHV 
6HFWLRQ 6\QRSVLV
SDJH7UHDWPHQW*URXSVDQG'XUDWLRQ
HGLWHGWRLQFOXGHVRWDWHUFHSWGRVLQJ
GXULQJWKH([WHQVLRQ3HULRG3DUWLFLSDQWVZLOOUHFHLYHVRWDWHUFHSW
HYHU\ZHHNV4:GXULQJWKH
([WHQVLRQ3HULRG
7DEOH6FKHGXOHRI
(YHQWV6R(
SDJHV6R(UHYLVHGWRUHPRYHWKH ZHHN
)ROORZ8S3HULRGWDEOHDQG
IRRWQRWHVUHYLVHGWRUHIOHFWRU
FODULI\WKHVHFKDQJHV$OOSDUWLFLSDQWVZLOOWUDQVLWLRQIURP
WKHZHHN7UHDWPHQW3HULRGWRWKH
PRQWK([WHQVLRQ3HULRG
7DEOH6R(
SDJHV([WHQVLRQ6R(WDEOHZLWK
IRRWQRWHVDGGHGWRSUHVHQWWKH
PRQWK([WHQVLRQ3HULRGDQGWKH
ZHHN)ROORZ8S3HULRGIRU DOO
SDUWLFLSDQWVHQUROOHG6R(WDEOHDGGHGWRSUHVHQWWKH
PRQWK([WHQVLRQ3HULRGDQG
ZHHN)ROORZ 8S3HULRGIRUDOO
SDUWLFLSDQWVHQUROOHG 
6HFWLRQ SDJH 5DWLRQDOHIRU'RVH/HYHODQG
)UHTXHQF\6HOHFWLRQUHYLVHGWRGLYLGHWKH
ZHHN7UHDWPHQW
3HULRGHYHU\ZHHNV>4:@
GRVLQJIURPWKH PRQWK
([WHQVLRQ3HULRG4:GRVLQJ'RVLQJ/HYHODQG)UHTXHQF\DUH
GLIIHUHQWGXULQJWKH ZHHN
7UHDWPHQW3HULRGDQGWKH PRQWK
([WHQVLRQ3HULRG 
6HFWLRQSDJH 5DWLRQDOHIRU2II6WXG\'UX J
$VVHVVPHQWVUHPRYHG $OOSDUWLFLSDQWVWUDQVLWLRQGLUHFWO\
IURPWKH ZHHN7UHDWPHQW3HULRG
WRWKHPRQWK([WHQVLRQ3HULRG
ZLWKRXWDQ2II6WXG\'UXJ3HULRG
7DEOHSDJHV  5HYLVHGWRUHSODFH2II6WXG\2II
6WXG\'UXJZLWK([WHQVLRQ3HULRG$OOSDUWLFLSDQWVWUDQVLWLRQGLUHFWO\
IURPWKH ZHHN7UHDWPHQW3HULRG
WRWKHPRQWK([WHQVLRQ3HULRG
ZLWKRXWDQ2II6WXG\'UXJ3HULRG
6HFWLRQ SDJH 2YHUDOO'HVLJQUHYLVHGWRLQFOXGH
GHVFULSWLRQRIWKH PRQWK
([WHQVLRQ3HULRGDQG ZHHN
)ROORZ8S3HULRG7RSUHVHQWWKH PRQWK([WHQVLRQ
3HULRGDQG ZHHN)ROORZ8S
3HULRGIRUDOOSDUWLFLSDQWVHQUROOHG[COMPANY_003] [COMPANY_003]
:%/
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184821]  2021 
Acceleron Pharma Inc.  Page 87 of 93 CONFIDENTIAL  Table  14: Protocol Amendment 02 to Protocol Amendment 03A Amendment History  
(Continued)  
Protocol Location  Description of Change  Brief Rationale  
Section 4.3, Standard of 
Care, page 25;  
Section 5.1, Inclusion 
Criteria, page 30;  
Section 8.5.5, Rescue 
Therapy Criteria, 
page  50; Appendix [ADDRESS_184822] of care (SOC) for PAH are 
considered stable. However, 
changes, removal, or addition of 
PAH therapi[INVESTIGATOR_159084] 90 days prior 
to enrollment are considered 
unstable SOC, and these subjects do 
not meet inclusion criteria 8.  
Section 4.6, Extension 
Period, page 25  18-month Extension Period inserted  To present the 18 -month Extension 
Period for all participants enrolled  
Section 4.7, Follow -up 
Period, page 26,  Follow -Up Period revised to 
describe follow -up for participants 
who terminate early from the study, 
participant in the 24 -week 
Treatment Period but choose not to 
enter the 18 -month Extension 
Period, and participants who 
complete the 24 -week Treatment 
Period and the 18 -month Extension 
Period  To clarify the Follow -Up Period for 
all participants enrolled  
Figure 1, page 27  Figure 1 edited to remove â€œplacebo -
controlled treatment periodâ€ from 
the 24 -week Treatment Period, 
remove the 16 -week Off Study 
Drug Follow -Up Period, include the 
18-month Extension Period, and the 
8-week Follow -Up Period  This P hase 2a study is open -label, 
not placebo controlled, changed to 
â€œTreatment Periodâ€  
To reflect study design 
modifications as described for all 
participants  
Section 4.8.1 , Extension 
Period, page 28  Extension Period section inserted to 
describe the Q4W dosin g schedule 
during the 18 -month Extension 
Period  In the 18 -month Extension Period, a 
dose regimen of Q4W will be 
evaluated, with dose adjustment as 
needed to maintain equivalent 
exposure  
  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184823]  2021 
Acceleron Pharma Inc.  Page 88 of 93 CONFIDENTIAL  Table  14: Protocol Amendment 02 to Protoco l Amendment 03A Amendment History  
(Continued)  
Protocol Location  Description of Change  Brief Rationale  
Section  4.10, Justificat ion 
for Dose, pages  28-29 Justification For Dose during the 
24-week Treatment Period (Q3W 
dosing) and the 18 -month 
Extension Period (Q4W dosing) 
edited to clarify exposures and 
exposure -matching during these 
treatment periods  To justify the [ADDRESS_184824] clarified 
for Inclusion criterion 5  Normalization of FVC (% predicted 
FVC) and FEV 1/FVC (% predicted 
FEV 1/FVC) are based on measure 
pulmonary function in a healthy 
normal population with [ADDRESS_184825] less than complete lungs. 
Therefore, further adjustment will 
be permitted, based on the 
remaining fraction of lung volume 
in subjects with a history of 
lobectomy or pneumonectomy.  
  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184826]  2021 
Acceleron Pharma Inc.  Page 89 of 93 CONFIDENTIAL  Table  14: Protocol Amendment 02 to Protocol Amendment 03A Amendment History  
(Continued)  
Protocol Location  Description of Change  Brief Rationale  
Table 6,  pages  35-36 Dose modifications clarified  
If target blood pressure (BP) is 
maintained at the subs equent cycle, 
dose can be escalated, if applicable.  
Consider phlebotomy until 
hemoglobin (Hgb)  < 16.0 g/dL; 
delay dose for 1 cycle.  
At the next cycle, if Hgb is:  
a) < 18.0 g/dL, reduce study 
drug by 1 dose level and 
restart dosing.  
If dose reductions were done due to 
an adverse event not related to 
study medication, the dose can be 
escalated when the adverse event is 
resolved. In cases of dose reduction 
due to increases in Hgb, the dose 
can be re -escalated after 2 
consecutive cycles in which Hgb 
values are stable and equal or lower 
than the upper limit of normal.  To clarify dose modifications due to 
adverse events  
Section  7.2, Withdrawal 
from Study, page 39  Withdrawal from the Study section 
revised to clarify rescue therapy 
and study withdrawal  To ensure that patients who need 
rescue therapy due to clinical 
worsening are withdrawn from the 
study  
Section 8, Study 
Assessments and 
Procedures, page 41  Study assessments revised to define 
End of Study (EOS) assessment and 
8-week Follow -Up for all 
partici pants  Study assessments revised to define 
EOS and 8 -week Follow -Up Period 
in the 18 -month Extension Period  
Section 8.2.1, (iCPET), 
page [ADDRESS_184827] (iCPET) Assessment clarified 
for participants at Cycle  9, 
Day 169, in the [ADDRESS_184828] changes in the 
SoE (Tables 3 and 4)  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184829]  2021 
Acceleron Pharma Inc.  Page 90 of 93 CONFIDENTIAL  Table  14: Protocol Amendment 02 to Protocol Amendment 03A Amendment  History  
(Continued)  
Protocol Location  Description of Change  Brief Rationale  
Section 8.2.2, Cardiac 
Magnetic Resonance 
Imaging, page [ADDRESS_184830]  
  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184831]  2021 
Acceleron Pharma Inc.  Page 91 of 93 CONFIDENTIAL  Substantive changes from the Protocol Amendment 01 (13 September 2018) to Protocol 
Amendment 02 (05 December 2018) are detailed below.  Minor edits are not included.  
Table  15: Protocol Amendment [ADDRESS_184832] been made 
for clarity.  Redundant and 
unnecessary footnotes were 
removed.  
Section 5.1, Inclusion 
Criteria  Inclusion criterion 8: increase 
6MWD upper limit  
 
 
Inclusion criterion 10: Contraceptive 
guidelines language clarified.  
Changed timing of the requirement 
for effective contraception use prior 
to starting investigational product 
from [ADDRESS_184833] 
from stable SOC.  
 
To align inclusion criterion with the 
Appendix 8 guidelines and 
definitions.  To align contraception 
guidelines with study timelines.  
Section 5.2, Exclus ion 
Criteria  Exclusion criterion 10: Changed the 
baseline hemoglobin level for 
exclusion for women from >  15 g/dL 
to > 16 g/dL  
Exclusion criterion 24: removed 
â€œactive on the lung transplant list.â€  To align the hemoglobin exclusion 
criterion for both gender s. 
 
To allow participants to enroll in the 
study if they are active on the lung 
transplant list and meet all other 
inclusion/exclusion criteria.  
Section 5.3, Screen 
Failures  Added details regarding capturing 
AEs and frequency of rescreening 
for screen fai lures.  To clarify that AE details are to be 
captured for screen failures and 
rescreening is allowed only once.  
Section 6.3, Dose 
Modification  Table 5: Changed the dose 
modification rules for AEs, 
hemoglobin, and blood pressure.  To align with updated 
inclusion/exclusion criteria and to 
clarify when doses of study drug 
should be delayed, reduced, or 
escalated.  
Section 7.1, 
Discontinuation of 
Study Treatment  Added that discontinuation of study 
treatment would occur if a subject 
has a QTcF >  500m s during the 
treatment period.  To ensure that participants who 
meet this threshold are discontinued 
appropriately.  
082WBL
Clinical Study Protocol   Sotatercept (ACE -011) 
Study No: A011 -10 
Revision: [ADDRESS_184834]  2021 
Acceleron Pharma Inc.  Page 92 of 93 CONFIDENTIAL  Table  15: Protocol Amendment 01 to Protocol Amendment 02 Amendment History  
(Continued)  
Protocol Location  Description of Change  Brief Rationale  
Section 8.4, Safety 
Assessments.  Weight was moved from the 
physical exam section (8.4.1) to the 
vital signs section (8.4.2).  Weight is collected and recorded in 
the eCRF as a part of the vital signs.  
Section 8.4.6, Clinical 
Safety Laboratory 
Assessments  Added, â€œIf hemoglobin is â‰¥  17 g/dL 
during Cycle 1 (Day 8) or Cycle 2 
(Day 30), participants should return 
weekly for hemoglobin monitoring.â€  To ensure that participants whose 
hemoglobin levels become high are 
appropriately monitored.  
Appendix 8, 
Contraceptive Guidance 
and Collection of 
Pregnancy Information  Contraceptive guidelines language 
clarified.   To align with Inclusion Criteria and 
study timelines.  
 
 
082WBL
&OLQLFDO6WXG\3URWRFRO  6 RWDWHUFHSW$&(
6WXG\1R$5HYLVLRQ
$XJXVW
$FFHOHURQ3KDUPD,QF 3DJHRI &21),'(17,$/6XEVWDQWLYHFKDQJH VIURPWKHSURWRFRO-XO\WR$PHQGPH QW6HSWHPEHUDUH
OLVWHGEHORZ0LQRUHGLWVDUHQRWLQFOXGHG
7DEOH 7KH2ULJLQDO3URWRFROWR3URWRFRO$PHQGPHQW$PHQGPHQW+ LVWRU\
3URWRFRO/RFDWLRQ 'HVFULSWLRQRI&KDQJH %ULHI5DWLRQDOH
7DEOHSDJH  0HGLFDOPRQLWRUDW$FFHOHURQ

5HPRYLQJ33'PHGLFDOPRQLWRU 0HGLFDOPRQLWRUKDVFKDQJHG
IURP WR 
ZKRZLOODOVRSHUIRUP
VDIHW\PRQLWRULQJ 
6\QRSVLV
6HFWLRQ6WXG\ 5DWLRQDOH
6HFWLRQ6WXG\'HVLJQ 
6HFWLRQ-XVWLILFDWLRQIRU'RVH
6HFWLRQ'RVH0RGLILFDWLRQ6WDUWLQJGRVHIRU&\FOHKDVEHHQ
FKDQJHGWRPJNJVWDUWLQJGRVH
IRU&\FOHV LVPJNJ7RUHGXFHWKHFKDQFHVRI
SDUWLFLSDQWVKDYLQJHOHYDWHG
KHPRJORELQ 
7DEOH6FKHGXOHRI(YHQWV
6HFWLRQ(IILFDF\
$VVHVVPHQWV 
x5HPRYHGTXDOLW\RIOLIH
DVVHVVPHQWVVHURORJ\DQGQRQ
LQYDVLYH&3(7
x0RYHG PLQXWHZDONWHVWIURP
&\FOHWR&\FOH
x7LPLQJRISULPDU\HQGSRLQW
DVVHVVPHQWFODULILHGDVRFFXUULQJ
DIWHUZHHNVRIWUHDWPHQW
x)ROORZ8S3HULRGGHILQHGDV
YLVLWV
x:LQGRZLQJDURXQG(QGRI6WXG\
YLVLWHGLWHGWR ZHHNVSRVWODVW
GRVHSOXVGD\VQRW SOXVPLQXV$VVHVVPHQWVDQGWLPHSRLQWV
KDYHEHHQHGLWHGWREHWWHU
FDSWXUHPHDQLQJIXOFKDQJHVDQG
WLPHSRLQWVWKURXJKRXWWKHVWXG\2WKHUHGLWVRI7U HDWPHQW3HULRG
)ROORZ
8S3HULRGDQG(26
KDYHEHHQPDGHIRUFODULW\ 
6HFWLRQ$GYHUVH(YHQWV $OO$(VVHULRXVDQGQRQVHULRXV
UHODWHGDQGQRQ UHODWHGDUHWREH
UHFRUGHGRQWKHH&5)IURPWKHWLPHRIVLJQLQJRIFRQVHQWWRWKH(26
YLVLW
&ODULILFDWLRQRQWKHLQWHQWRI
FDSWXULQJDOO$(V 
[COMPANY_003] [COMPANY_003] [COMPANY_003]
:%/